

# THE BIOSTATISTICS CENTER PUBLICATIONS LIST

\*

GENERAL DIRECTORY

# TABLE OF CONTENTS

<i>PUBLICATIONS ORGANIZED BY ACTIVITY</i> .....	3
STATISTICAL METHODS – ARTICLES PUBLISHED .....	3
STATISTICAL METHODS – BOOKS PUBLISHED.....	13
CLINICAL TRIALS AND EPIDEMIOLOGIC METHODS – ARTICLES PUBLISHED .....	14
CLINICAL TRIALS AND EPIDEMIOLOGIC METHODS – BOOKS PUBLISHED .....	19
<i>RESULTS OF MEDICAL INVESTIGATION</i> .....	20
ANGIOTENSIN CONVERTING ENZYME INHIBITION IN DIABETIC NEPHROPATHY (ACE) .....	20
CENTER FOR CONSUMER HEALTH EDUCATION PROGRAM.....	20
CENTER TO PROTECT WORKERS RIGHTS .....	21
CHORIONIC VILLUS SAMPLING (CVS) .....	21
CLINICAL STUDY OF INTERMITTENT POSITIVE PRESSURE BREATHING.....	22
DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT) .....	23
DIABETES PREVENTION PROGRAM (DPP) .....	29
DICHLOROACETATE-LACTIC ACIDOSIS STUDY GROUP.....	35
RANDOMIZED TRIAL OF 11-14 WEEK AMNIOCENTESIS AND TRANSABDOMINAL CVS (EATA) – FIRST TRIMESTER MATERNAL SERUM BIOCHEMISTRY AND FETAL NUCHAL TRANSLUCENCY SCREENING ANCILLARY STUDY (BUN) .....	36
THE EFFECTS OF MATERNAL LIFESTYLE ON INFANT OUTCOMES (EMLI).....	37
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) .....	38
<i>PPG Publications (Under EDIC)</i> .....	43
<i>LIPOPROTEIN DISTRIBUTION/OBESITY GROUP (Under EDIC)</i> .....	44
<i>Genetics Studies (Under EDIC)</i> .....	45
FIRST AWARD .....	45
GENETICS OF KIDNEYS IN DIABETES (GOKIND) .....	45
GIRLS HEALTH ENRICHMENT MULTI-SITE STUDIES (GEMS) .....	45
LUPUS NEPHRITIS COLLABORATIVE STUDY GROUP.....	46
MATERNAL FETAL MEDICINE UNITS (MFMU) .....	47
MEDICAL INFORMATION MANAGEMENT SYSTEMS (MIMS).....	73
MEDICAL THERAPY OF PROSTATIC SYMPTOMS (MTOPS).....	73
MYOCARDIAL INFARCTION AND THE ROLE OF ORAL CONTRACEPTIVES .....	74
NATIONAL COOPERATIVE GALLSTONE STUDY .....	74
NATIONAL EXERCISE AND HEART DISEASE PROJECT .....	77
NEONATAL INTENSIVE CARE UNITS NETWORK (NICU).....	77
OPTIC NEURITIS TREATMENT TRIAL .....	81
PEPTIDE T.....	83
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITION (PEACE).....	84
PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DIAGNOSIS (PIOPED II) .....	85
ROUTINE ANTENATAL DIAGNOSTIC IMAGING WITH ULTRASOUND (RADIUS).....	86
SARCOIDOSIS GENETIC ANALYSIS (SAGA).....	86
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): (TODAY AND HEALTHY) .....	87
TYPE 1 DIABETES TRIALNET (TRIALNET) .....	87
VIETNAM HEAD INJURY STUDY .....	88
THE WOMEN’S HEALTH STUDY .....	88
OTHER MEDICAL INVESTIGATIONS.....	89

## THE BIostatISTICS CENTER

### TOTAL PUBLICATIONS BY SUBJECT AREA:

Statistical Methods - Articles:	156
Statistical Methods - Books	2
Clinical Trials and Epidemiologic Methods – Articles:	67
Clinical Trials and Epidemiologic Methods – Books:	1
Results of Medical Investigations:	<u>586</u>
TOTAL:	812

## ***PUBLICATIONS ORGANIZED BY ACTIVITY***

---

### **STATISTICAL METHODS – ARTICLES PUBLISHED**

156. Lachin, JM. "Sample Size Evaluation for a Multiply Matched Case-Control Study Using the Score Test from a Conditional Logistic (Discrete Cox PH) Regression Model." *Statistics in Medicine*, 27:2509-2523, **2008**.
155. Lachin JM, Younes N. A composite design for transition from a preliminary to a full-scale study. *Statistics in Medicine* **2007**; 26:5014–5032.
154. Sparling YH, Younes N, Lachin JM, and Bautista OM. "Parametric Survival Models for Interval-Censored Data with Time-Dependent Covariates." *Biostatistics*, 7.4: 599-614, **2006**.
153. Lachin JM. "Operating Characteristics of Sample Size Re-estimation with Futility Stopping Based on Conditional Power." *Statistics in Medicine*, 25:3348-3365, **2006**.
152. Lachin JM. "Maximum Information Designs." *Clinical Trials*, 2:453-464, **2005**.
151. Lachin JM. "A Review of Methods for Futility Stopping Based on Conditional Power." *Statistics in Medicine*, 24:2747-2764, **2005**.

150. Greenhouse JB and Lachin JM. "Greenhouse, Samuel W." In Encyclopedia of Biostatistics. Second Edition. P. Armitage and T. Colton (Eds.), 2251-3. John Wiley & Sons, Ltd. Chichester, **2005**.
149. Lachin, JM. "Conflicts of Interest in Data Monitoring of Industry Versus Publicly Financed Clinical Trials." *Statistics in Medicine*, 23:1519-1521, **2004**.
148. Lachin JM, Greenhouse SW and Bautista OM. "Group Sequential Large Sample  $T^2$ -like  $X^2$  Tests for Multivariate Observations." *Statistics in Medicine*, 22:3357-68, **2003**.
147. Lan KKG, Lachin JM and Bautista OM. "Over-Ruling a Group Sequential Boundary – a Stopping Rule Versus a Guideline." *Statistics in Medicine*, 22:3347-55, **2003**.
146. Greenhouse, SW. "On Psychiatry, Epidemiology and Statistics: A View from the 1950s and 1960s." *Statistics in Medicine*, 22.21: 3311-22, **2003**.
145. Lachin, JM. "A Tribute to Samuel W. Greenhouse." *Statistics in Medicine*, 22:3267-76, **2003**.
144. Hu M and Lachin JM. "Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters." *Communications in Statistics: Simulation and Computation*, 32.3: 619-39, **2003**.
143. Rochon R and Gillespie BW. "A Methodology for Analyzing a Repeated Measured and Survival Outcome Simultaneously." *Statistics in Medicine*. 20.8: 1173-84, April **2001**.
142. Hu M and Lachin JM. "Application of Robust Estimating Equations to the Analysis of Quantitative Longitudinal Data." *Statistics in Medicine*, 20: 3411-3428, **2001**.
141. Li Z and Zhang H. "Mapping Quantitative Trait Loci in Humans Using Both Extremely Discordant and Concordant Sib Pairs: A Unified Approach for Meta Analysis." *Communications in Statistics*, 29:1115-1127, **2000**.
140. Bautista OM, Bain RP, and Lachin JM. "A Flexible Stochastic Curtailing Procedure for the Log-Rank Test." *Controlled Clinical Trials*, 21:428-439, **2000**.
139. Lachin JM. "Statistical Considerations in the Intent-to Treat Principle." *Controlled Clinical Trials*, 21: 167-189, **2000**.
138. Hu MX and Lachin JM. "Likelihood-Based Approaches for Handling Nuisance Parameters." *American Statistical Association Proceedings of the Section on Bayesian Statistical Science*, 108-113, **1999**.
137. Li Zhaohai. "A Conversation with Chin Long Chiang." *Statistical Science*, 14: 457-470, **1999**.

136. The BMI in Diverse Populations Collaborative Group (Li Zhaohai, co-author). "Effect of Smoking on the Body Mass Index-Mortality Relation: Empirical Evidence from 15 Studies." *American Journal of Epidemiology*, 150: 1297-1308, **1999**.
135. Lachin JM. Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. *Controlled Clinical Trials*, 20: 408-422, **1999**.
134. Rochon J. Issues in Adjusting for Covariates Arising Postrandomization in Clinical Trials. *Drug Information Journal*, 33:1219-1228, **1999**.
133. Rochon J. Application of GEE Procedures for Sample Size Calculations in Repeated Measures Experiments. *Statistics in Medicine*, 17:1643-1658, **1998**.
132. Lachin JM. Sample size determination. In Armitage P and Colton T, editors, *Encyclopedia of Biostatistics*. New York: Wiley, 3892-3903, **1998**.
131. Todorov AA, Vogler GP, Gu C, Province MA, Li Z, Heath AC and Rao DC. "The Testing Causal Hypotheses in Multivariate Linkage Analysis of Quantitative Traits: General Formulation and Application to Sibpair Data." *Genetic Epidemiology*, 15:263-278, **1998**.
130. McGee Daniel, Li Zhaohai, Durazo-Arvizu R and Cooper R. "Some Preliminary Observations on a Meta-Analysis of Body Mass Index and Mortality." In *1997 Proceedings of the Statistics in Epidemiology, American Statistical Association*, Sections 1-10, **1998**.
129. Durazo-Arvizu R, McGee D, Li Z and Cooper R. "Establishing the Nadir of the Body Mass Index-Mortality Relationship: A Case Study." *Journal of the American Statistical Association*, 92:1312-1319, **1997**.
128. Younes N and Lachin JM. Link-Based Models for Survival Data with Interval and Continuous Time Censoring. *Biometrics*, 53: 1199-1211, **1997**.
127. Lachin JM. Group sequential monitoring of distribution-free analyses of repeated measures. *Statistics in Medicine*, 16:653-668, **1997**.
126. Rochon J. Analyzing Bivariate Repeated Measures for Discrete and Continuous Outcome Variables. *Biometrics*, 52:740-750, **1996**.
125. Rochon J. Accounting for Covariates Observed Post Randomization for Discrete and Continuous Repeated Measures Data. *Journal of the Royal Statistical Society, Series B*, 58:205-219, **1996**.
124. Lachin JM. Distribution-Free Marginal Analysis of Repeated Measures. *Drug Information Journal*, 30:1017-1028, **1996**.
123. Rochon J. Supplementing the Intent-to-Treat Analysis: Accounting for Covariates Observed Post Randomization in Clinical Trials. *Journal of the American Statistical Association*, 90:292-300, **1995**.

122. Lachin JM and Bautista OM. Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. In Thall:PF, editor, *Recent Advances in Clinical Trials Design and Analysis*. Boston: Kluwer: 203-223, **1995**.
121. Lan KKG, Rosenberger WF and Lachin JM. Sequential Monitoring of Survival Data with the Wilcoxon Statistic. *Biometrics*, 51:1175-1183, **1995**.
120. Lan KKG and Lachin JM. Martingales without Tears. *Lifetime Data Analysis*, 1:361-375, **1995**.
119. Rosenberger WF, Lachin JM and Bain RP. Nonparametric test of stochastic ordering for multiple longitudinal measures. *Journal of Biopharmaceutical Statistics*, 5:235-243, **1995**.
118. Lachin JM. Discussion: Adaptive designs in clinical trials: Lilly experience. *Biopharmaceutical Report*, 3:6, **1995**.
117. Rosenberger WF. Adaptive Designs in Clinical Trials: Some Issues with Emphasis on Asymptotic Inference. In Flournoy N and Rosenberger WF, editors, Adaptive Designs. Hayward, CA: *Institute of Mathematical Statistics*: 25:1-12, **1995**.
116. Smythe RT and Rosenberger WF. Play-the-Winner Designs, Generalized Pólya Urns, and Markov Branching Processes. In Flournoy N and Rosenberger WF, editors, Adaptive Designs. Hayward: CA, *Institute of Mathematical Statistics*, 25:13-21, **1995**.
115. DeMets DL and Lan KKG. Interim analysis: The alpha spending function approach. *Statistics in Medicine*, 13:1341-1352, **1994**.
114. Lan KKG, Reboussin DM and DeMets DL. Information and information fractions for design and sequential monitoring of clinical trials. *Communications in Statistics*, 23:403-420, **1994**.
113. Palesch YY and Lachin JM. Asymptotically Distribution-Free Multivariate Rank Tests for Multiple Samples with Partially Incomplete Observations. *Statistica Sinica*, 4:373-387, **1994**.
112. Rosenberger WF. Asymptotic Inference with Response-Adaptive Treatment Allocation Designs. *The Annals of Statistics*, 21:2098-2107, **1993**.
111. Lan KKG, Rosenberger WF and Lachin JM. Use of Spending Functions for Occasional or Continuous Monitoring of Data in Clinical Trials. *Statistics in Medicine*, 12:2219-2231, **1993**.
110. Lan KKG and Zucker DM. Sequential Monitoring of Clinical Trials: The Role of Information and Brownian Motion. *Statistics in Medicine*, 12:753-765, **1993**.
109. Su JQ and Lachin JM. Group sequential distribution-free methods for the analysis of multivariate observations. *Biometrics*, 48:1033-1042, **1992**.
108. Wu MC and Lan KKG. Sequential monitoring for comparison of changes in a response variable in clinical studies. *Biometrics*, 48:765-779, **1992**.

107. Lachin JM. Power and sample size evaluation for the McNemar test with application to matched case-control studies. *Statistics in Medicine*, 11:1239-1251, **1992**.
106. Lachin JM. Some Large-Sample Distribution-Free Estimators and Tests for Multivariate Partially Incomplete Data from Two Populations. *Statistics in Medicine*, 11:1151-1170, **1992**.
105. Lakatos E and Lan KKG. A comparison of sample size methods for the logrank statistic. *Statistics in Medicine*, 11:179-191, **1992**.
104. Baker SG, Rosenberger WF, and Dersimonian R. Closed-form estimates for missing counts in two-way contingency tables. *Statistics in Medicine*, 11:643-657, **1992**.
103. Gu MG, Lai TL and Lan KKG. Rank Tests Based on Censored Data and Their Sequential Analogues. *American Journal of Mathematical and Management Sciences*, 11:147-176, **1991**.
102. Knoke JD. Nonparametric analysis of covariance for comparing change in randomized studies with baseline values subject to error. *Biometrics*, 47:523-533, **1991**.
101. Greenhouse SW, Zelen M, Gehan EA, Freidewald W, DeMets D, Ware JH, Gordon T, Lachin JM and Wittes J. Colton T, editor. "Remembrances of Max Halperin." *Statistics in Medicine*, 9:863-870, **1990**.
100. Wei LJ, Su JQ and Lachin JM. Interim analyses with repeated measurements in a sequential clinical trial. *Biometrika*, 77:359-364, **1990**.
99. Lan KKG and Lachin JM. Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. *Biometrics*, 46:759-770, **1990**.
98. Thall PF, and Vail SC. Some covariance models for longitudinal count data with overdispersion. *Biometrics*, 46:657-671, **1990**.
97. Wei LJ, Smythe RT, Lin DY and Park TS. Statistical inference with data-dependent treatment allocation rules. *Journal of the American Statistical Association*, 85:156-162, **1990**.
96. Wei LJ, Su JQ and Lachin JM. Interim analyses with repeated measurements in a sequential clinical trial. *Biometrika*, 77:359-64, **1990**.
95. Lachin JM, Matts JP and Wei LJ. Response to Letter to the Editor: Permutation tests following restricted randomization procedures. *Controlled Clinical Trials*, 11:150-152, **1990**.
94. Greenhouse SW. Comment. *Statistics in Medicine*, 9:371-372, **1990**.
93. Lan KKG and Wittes J. Linear Rank Tests for Survival Data: Equivalence of Two Formulations. *The American Statistician*, 44:23-26, **1990**.
92. Thall PF and Simon R. Incorporating Historical Control Data in Planning Phase II Clinical Trials. *Statistics in Medicine*, 9:215-228, **1990**.

91. Thall PF, Simon R and Ellenberg SS. A Two-Stage Design for Choosing Among Several Experimental Treatments and a Control in Clinical Trials. *Biometrics*, 45:537-547, **1989**.
90. Halperin M, Hamdy MI and Thall PF. Distribution-Free Confidence Intervals for a Parameter of Wilcoxon-Mann-Whitney Type for Ordered Categories and Progressive Censoring. *Biometrics*, 45:509-521, **1989**.
89. Wei LJ, Smythe RT and Mehta CR. Interval estimation with restricted randomization rules. *Biometrika*, 76:363-368, **1989**.
88. Smythe RT. Conditional Inference for Restricted Randomization Designs. *The Annals of Statistics*, 16:1155-1161, **1988**.
87. Snapinn SM and Knoke JD. Bootstrapped and Smoothed Classification Error Rate Estimators. *Communications in Statistics - Simulation*, 17:1135-1153, **1988**.
86. Lachin JM, Matts JP and Wei LJ. Randomization in clinical trials: Conclusions and recommendations. *Controlled Clinical Trials*, 9:365-374, **1988**.
85. Wei LJ and Lachin JM. Properties of the Urn Randomization in Clinical Trials. *Controlled Clinical Trials*, 9:345-364, **1988**.
84. Matts JP and Lachin JM. Properties of permuted-block randomization in clinical trials. *Controlled Clinical Trials*, 9:327-344, **1988**.
83. Lachin JM. Properties of Simple Randomization in Clinical Trials. *Controlled Clinical Trials*, 9:312-326, **1988**.
82. Lachin JM. Statistical properties of randomization in clinical trials. *Controlled Clinical Trials*, 9:289-311, **1988**.
81. Lachin JM. Properties of randomization in clinical trials: Forward. *Controlled Clinical Trials*, 9:287-288, **1988**.
80. Lachin JM and Wei LJ. Estimators and Tests in the Analysis of Multiple Nonindependent 2 x 2 Tables with Partially Missing Observations. *Biometrics*, 44:513-528, **1988**.
79. Thall PF. Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data. *Biometrics*, 44:197-209, **1988**.
78. Thall PF and Lachin JM. Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. *Journal of the American Statistical Association*, 83:339-347, **1988**.
77. Halperin M, Lan KKG and Hamdy MI. Some implications of an alternative definition of the multiple comparison problem. *Biometrika*, 75:773-778, **1988**.
76. Halperin M and Lan KKG. A Two Sample Ordered Alternative Test for Means and Variances. *Communications in Statistics-Theory Methods*, 16:1297-1313, **1987**.

75. Halperin M, Lan KKG, Wright EC and Foulkes MA. Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies. *Controlled Clinical Trials*, 8:315-326, **1987**.
74. Halperin M, Gilbert PR and Lachin JM. Distribution Free Confidence Intervals for  $\Pr(X_1 < X_2)$ . *Biometrics*, 43:71-80, **1987**.
73. Lachin JM and Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. *Biometrics*, 42:507-519, **1986**.
72. Pipberger HV, Doyle JT, Schlesselman S, Pipberger HA, Halperin M, McManus CD, Appel M and Yamamoto WS. The Orthogonal Electrocardiogram as Risk Indicator for the Prediction of Myocardial Infarction and/or Cardiac Death. *Journal of Electrocardiology*, 19:327-336, **1986**.
71. Thall PF and Lachin JM. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. *Statistics In Medicine*, 5:73-83, **1986**.
70. Wei LJ and Pee D. Distribution-free methods of estimating location difference with censored paired data. *Journal of the American Statistical Association*, 80:405-410, **1985**.
69. Wei LJ and Johnson WE. Combining dependent tests with incomplete repeated measurements. *Biometrika*, 72:359-364, **1985**.
68. Halperin M, Abbott RD, Blackwelder WC, Jacobowitz R, Lan KKG, Verter JI, and Wedel H. On the Use of the Logistic Model in Prospective Studies. *Statistics in Medicine*, 4: 227-235, **1985**.
67. Padgett WJ and Wei LJ. Interval estimation after sequential testing based on the total time on test. *Operations Research*, 32:726-731, **1984**.
66. Wei LJ. Testing goodness of fit for proportional hazards model with censored observations. *Journal of the American Statistical Association*, 79:649-652, **1984**.
65. Wei LJ and Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. *Journal of the American Statistical Association*, 79:653-661, **1984**.
64. Lan KKG, Simon R and Halperin M. Stochastically curtailed tests in long-term clinical trials. *Communications in Statistics*, 1:207-219, **1982**.
63. Lan KKG, Halperin M and Waldman GT. Grouping and linear regression. *Journal of Chronic Diseases*, 35:245-249, **1982**.
62. DeMets DL and Halperin M. Early stopping in the two-sample problem for bounded random variables. *Controlled Clinical Trials*, 3:1-11, **1982**.
61. Mantel N. Impractical bounds on differences of order statistics. *The American Statistician*, 36:65, **1982**.

60. Mantel N. Jerome Cornfield and statistical applications to laboratory research: A personal reminiscence. *Biometrics Supplement: Current Topics in Biostatistics and Epidemiology*, 38:17-23, **1982**.
59. Mantel N, Tukey JW, Ciminera JL and Heyse JF. Tumorigenicity Assays, Including Use of the Jackknife. *Biometrical Journal*, 24: 579-596, **1982**.
58. Halperin M and Johnson NJ. Design and sensitivity evaluation of follow-up studies for risk factor assessment. *Biometrics*, 37:805-810, **1981**.
57. Lachin JM. Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. *Biometrics*, 37: 87-101, **1981**.
56. Lachin JM. Introduction to Sample Size Determination and Power Analysis for Clinical Trials. *Controlled Clinical Trials*, 2: 93-113, **1981**.
55. Mantel N and Halperin M. The Baptista-Pike algorithm (AS115). *The Journal of the Royal Statistical Society*, 30:73-75, **1981**.
54. Mantel N. Calculation of scores for a Wilcoxin generalization applicable to data subject to arbitrary right censorship. *The American Statistician*, 35:244-246, **1981**.
53. Mantel N. Lognormal analyses of data on worker exposure to air contaminants. *Biometrics*, 37:833-834, **1981**.
52. Mantel N. Randomization tests when there are non-responders. *Biometrics*, 36:552-553, **1980**.
51. Mantel N. Assessing laboratory evidence for neoplastic activity. *Biometrics*, 36:381-399, **1980**.
50. Mantel N. Biased inferences in tests for average partial associations. *The American Statistician*, 34:190-191, **1980**.
49. Mantel N and Fleiss JL. Minimum Expected Cell Size Requirements for the Mantel-Haenszel One-Degree-of-Freedom Chi-Square Test and a Related Rapid Procedure. *American Journal of Epidemiology*, 112: 129-134, **1980**.
48. Mantel N. Obituary: Jerome Cornfield 1912-1979. *Biometrics*, 36:357-358, **1980**.
47. Mantel N. Comparisons with a known survival curve. *Biometrics*, 36:355-356, **1980**.
46. Mantel N and Rahe AJ. Differentiated Sign Tests. *International Statistical Review*, 48 :19-28, **1980**.
45. Mantel N. Limited usefulness of mathematical models for assessing the carcinogenic risk of minute doses. In Quantitative aspects of risk assessment in chemical carcinogenesis. *Archives of Toxicology*, 3:305-310, **1980**.
44. Halperin M, Ware JH, and Wu M. Conditional distribution-free tests for the two-sample problem in the presence of right censoring. *Journal of the American Statistical Association*, 75:638-645, **1980**.

43. Mantel N and Ciminera JL. Use of logrank scores in the analysis of litter-matched data on time to tumor appearance. *Cancer Research*, 39:4308-4315, **1979**.
42. Gail MH, Weiss GH, Mantel N and O'Brien SJ. A Solution to the Generalized Birthday Problem with Application to Allozyme Screening for Cell Culture Contamination. *Journal of Applied Probability*, 16: 242-251, **1979**.
41. Mantel N. Multidimensional contingency table analysis. *The American Statistician*, 33:93, **1979**.
40. Mantel N. Ridit analysis and related ranking procedures - use at your own risk. *American Journal of Epidemiology*, 109:25-29, **1979**.
39. Cornfield J. Randomization by group: A formal analysis. *American Journal of Epidemiology*, 108:100-102, **1978**.
38. Cornfield J. Reply to Letter to the Editor: Models for carcinogenic risk assessment. *Science*, 202:1107-1108, **1978**.
37. Mantel N and Byar DP. Marginal Homogeneity, Symmetry, and Independence. *Communications in Statistics - Theory and Methods*, A7:953-976, **1978**.
36. Mantel N and Hankey BF. A Logistic Regression Analysis of Response-Time Data Where the Hazard Function is Time Dependent. *Communications in Statistics - Theory and Methods*, A7: 333-347, **1978**.
35. Lachin JM. Prog Lachin, a computer program for the Lachin (1973) procedure. In Goldstein M and Dillon WR, editors, *Discrete Discriminant Analysis*. New York: Wiley, 153-168, **1978**.
34. Lachin JM. Sample size determinations for  $r \times c$  comparative trials. *Biometrics*, 33:315-324, **1977**.
33. Cornfield J. Carcinogenic risk assessment. *Science*, 198: 693-699, **1977**.
32. Cornfield J and Detre K. Bayesian life table analysis. *The Journal of the Royal Statistical Society, Series B*, 39:86-94, **1977**.
31. Cornfield J, Dunn RA and Pipberger HV. The statistical basis of computerized diagnosis using the electrocardiogram. In Van Ryzin J, editor, *Classification and Clustering*. New York: Academic Press, 355-369, **1977**.
30. Cornfield J and Mantel N. "Safe doses" in carcinogenic experiments. *Biometrics*, 33:21-30, **1977**.
29. Gail M and Mantel N. Counting the number of  $r \times c$  contingency tables with fixed margins. *Journal of the American Statistical Association*, 72:859-862, **1977**.
28. Mantel N. Do we want confidence intervals symmetrical about the null value? *Biometrics*, 33:759-760, **1977**.

27. Mantel N. Response to Open Query: Theoretical problems in the modified Mantel-Bryan procedure. *Biometrics*, 33:752-757, **1977**.
26. Mantel N. Tests and limits for the common odds ratio of several 2x2 contingency tables: Methods in analogy with the Mantel-Haenszel procedure. *Journal of Statistical Planning and Inference*, 1:179-189, **1977**.
25. Mantel N, Bohidar NR, and Ciminera JL. Mantel-Haenszel analyses of litter-matched time-to-response data, with modifications for recovery of interlitter information. *Cancer Research*, 37:3863-3868, **1977**.
24. Halperin M, Ware JH, Byar DP, Mantel N, Brown CC, Koziol J, Gail M and Green SB. Testing for interaction in an IxJxK contingency table. *Biometrika*, 64:271-275, **1977**.
23. Mantel N, Brown C and Byar DP. Tests for homogeneity of effect in an epidemiologic investigation. *American Journal of Epidemiology*, 106:125-129, **1977**.
22. Mantel N. Contingency tables—a reply. *The American Statistician*, 31:135, **1977**.
21. Mantel N. How to guarantee significance. *The American Statistician*, 30:201-202, **1976**.
20. Mantel N, Kryscio RJ and Myers MH. Tables and formulas for extended use of the Ederer-Myers-Mantel disease-clustering procedure. *American Journal of Epidemiology*, 104:576-584, **1976**.
19. Mantel N. Transformations and the income tax. *The American Statistician*, 30:124-129, **1976**.
18. Mantel N. Complex analysis of a simple dilution experiment. *Biometrics*, 32:487-489, **1976**.
17. Mantel N. The continuity correction. *The American Statistician*, 30:103, **1976**.
16. Mantel N. Group testing with the goal of estimation. *Biometrics*, 31:994-995, **1975**.
15. Byar DP and Mantel N. Some interrelationships among the regression coefficient estimates arising in a class of models appropriate to response-time data. *Biometrics*, 31:943-947, **1975**.
14. Mantel N and Hankey BF. The odds ratios of a 2x2 contingency table. In Proceedings of the 40<sup>th</sup> Session of the International Statistical Institute, Warsaw 1975. Bulletin of the International Statistical Institute, 46:128-136, **1975**.
13. Mantel N and Hankey BF. The odds ratios of a 2x2 contingency table. *The American Statistician*, 29:143-145, **1975**.

12. Mantel N. "Branching Experiments: A generalized application of the life-table method." In Ludwig D and Cooke KL, editors, *Epidemiology, Proceedings of a SIMS conference on epidemiology, Alta, Utah, July 8-12, 1974. Philadelphia: Society for Industrial and Applied Mathematics*, 69-74, **1975**.
11. Mantel N and Schneiderman MA. Reply to. *Cancer Research*, 35:3213, **1975**.
10. Mantel N and Schneiderman MA. Non-parametric interval estimation of relative potency for dilution assays, including the case of non-monotone dosage response curves. *Biometrics*, 31:619-632, **1975**.
9. Mantel N and Schneiderman MA. Estimating "safe" levels, a hazardous undertaking. *Cancer Research*, 35:1379-1386, **1975**.
8. Mantel N, Bohidar NR, Brown CC, Ciminera JL and Tukey JW. An improved Mantel-Bryan procedure for "safety" testing of carcinogens. *Cancer Research*, 35:865-872, **1975**.
7. Mantel N and Fleiss JL. The equivalence of the generalized McNemar tests for marginal homogeneity in  $2^3$  and  $3^2$  tables. *Biometrics*, 31:727-729, **1975**.
6. Cornfield J. A statistician's apology. *Journal of the American Statistical Association*, 70:7-14, **1975**.
5. Cornfield J. Bayesian statistics. In *Proceedings of the Nineteenth Conference on the Design of Experiments in Army Research Development and Testing, U. S. Army Research Office Report 74-1, Office of the Chief of Research Development and Acquisition: 1-12, 1974*.
4. Mantel N. The distribution of ties and other events with probability zero. *The American Statistician*, 28:164, **1974**.
3. Ederer F and Mantel N. Confidence limits on the ratio of two Poisson variables. *American Journal of Epidemiology*, 100:165-167, **1974**.
2. Mantel N. Comment and a suggestion on W.J. Conover's: Some reasons for not using the Yates continuity correction on 2x2 contingency tables. *Journal of the American Statistical Association*, 69:374-382, **1974**.
1. Cornfield J. Statistical classification methods. Computer Diagnosis and Diagnostic Methods. In Jacquez JA, editor, *Proceedings of 2<sup>nd</sup> Conference on Diagnostic Methods, U. of Michigan*. Springfield, Illinois: Charles C. Thomas, 108-130, **1972**.

## **STATISTICAL METHODS – BOOKS PUBLISHED**

2. Lachin, J.M. Biostatistical Methods: The Assessment of Relative Risks. John Wiley and Sons, **2000**. (ISBN: 0-471-36996-9)

1. Tygstrup N, Lachin J, and Juhl E, editors. The Randomized Clinical Trial and Therapeutic Decisions. Marcel-Dekker, **1982**. (ISBN: 0-8247-1856-9).

## **CLINICAL TRIALS AND EPIDEMIOLOGIC METHODS – ARTICLES PUBLISHED**

67. Lachin JM, Cleary PA, Crofford C, Genuth S, Nathan D, Clark C, Ferris F, Siebert C for the DCCT Research Group. “Early Termination of the Diabetes Control and Complications Trial.” In Data Monitoring in Clinical Trials: A Case Studies Approach, DL DeMets, CD Furberg, LM Friedman (Eds). Springer, New York, New York, pp. 93-108, **2006**.
66. Lachin JM. “Conflicts of Interest in Data Monitoring of Industry Versus Publicly Financed Clinical Trials.” *Statistics in Medicine*, 23:1519-1521, **2004**.
65. Lachin JM. “The Role of Measurement Reliability in Clinical Trials.” *Clinical Trials*, 1:553-566, **2004**.
64. Dickersin K, Davis BR, Dixon DO, George SL, Hawkins BS, Lachin JM, Peduzzi P, Pocock S. “The Society for Clinical Trials Supports United States Legislation Mandating Trials Registration.” *Clinical Trials*, 1:417-420, **2004**.
63. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. “C-peptide is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve Beta-Cell Function: Report of an ADA Workshop, 21-22 October 2001.” *Diabetes*, 53:250-264, **2004**.
62. Lachin, JM. “Statistical Considerations in the Intent-to-Treat Principle.” *Controlled Clinical Trials*, 21:167-189, **2000**.
61. Zelitch-Yanovski S, Bain RP and Williamson DF. “Report of a National Institutes of Health-Centers for Disease Control and Prevention Workshop on the Feasibility of Conducting a Randomized Clinical Trial to Estimate the Long-Term Health Effects of Intentional Weight Loss in Obese Persons.” *American Society for Clinical Nutrition*, 69:366-72, **1999**.
60. Lachin, JM. Worst-rank score analysis with informatively missing observations in clinical trials. *Controlled Clinical Trails*, 20:408-422, **1999**.
59. Lachin JM. Discussion: Adaptive designs in clinical trials: The Lilly experience. *Biopharmaceutical Report*, 3:6, **1995**.

58. Rosenberger WF and Lachin JM. The use of response-adaptive designs in clinical trials. *Controlled Clinical Trials*, 14:471-484, **1993**.
57. Lachin JM and Lan SL. Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. *Controlled Clinical Trials*, 13:62-79, **1992**.
56. Rosenberger WF. Letter to the Editor: Circumcision and urinary tract infection. *Journal of the American Medical Association*, 268:55, **1992**.
55. Halperin M, DeMets DL and Ware JH. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. *Statistics in Medicine*, 9:881-892, **1990**.
54. Greenhouse SW. Some historical and methodological developments in early clinical trials at the National Institutes of Health. *Statistics in Medicine*, 9:893-901, **1990**.
53. Gordon T. Letter to the editor: Plasma triglyceride as a risk factor for coronary heart disease: The epidemiologic evidence and beyond. *American Journal of Epidemiology*, 131:942, **1990**.
52. Gordon T. Statistics in a prospective study: The Framingham Study. In *Proceedings of the American Statistical Association Sesquicentennial Invited Paper Sessions, ASA, Washington, DC, August 6-10*, 719-726, **1989**.
51. Schilling RJ and Bain RP. Prediction of children's blood lead levels on the basis of household-specific soil lead levels. *American Journal of Epidemiology*, 128:197-205, **1988**.
50. Gordon T. The diet-heart idea: Outline of a history. *American Journal of Epidemiology*, 127:220-225, **1988**.
49. Lachin JM and Wright EC. Statistical considerations in the design and analysis of clinical trials of causal therapy in cirrhosis of the liver. In Tygstrup N and Orlandi F, editors, *Cirrhosis of the Liver: Methods and Fields of Research*. Amsterdam: Elsevier, 461-472, **1987**.
48. Lan KKG, DeMets DL and Halperin M. More flexible sequential and non-sequential designs in long-term clinical trials. *Communications in Statistics - Theory and Methods, Simulation and Computation*, 13:2339-2353, **1984**.
47. Gordon T, Fisher M and Rifkind BM. Some difficulties inherent in the interpretation of dietary data from free-living populations. *Journal of Clinical Nutrition*, 39:152-156, **1984**.
46. Lachin JM. Statistical elements of the randomized clinical trial. In Tygstrup N, Lachin J, Juhl E, editors, *The Randomized Clinical Trial and Therapeutic Decisions*. New York: Marcel-Dekker, 77-103, **1982**.
45. Lachin, JM. Statistical inference in clinical trials. In Tygstrup N, Lachin J, Juhl E, editors, *The Randomized Clinical Trial and Therapeutic Decisions*. New York: Marcel-Dekker, 117-143, **1982**.

44. Lachin, JM. Statistical analysis of the randomized clinical trial. In Tygstrup N, Lachin J, Juhl E, editors, *The Randomized Clinical Trial and Therapeutic Decisions*. New York: Marcel-Dekker, 155-197, **1982**.
43. Lachin, JM. The execution of a protocol. In Tygstrup N, Lachin J, Juhl E, editors, *The Randomized Clinical Trial and Therapeutic Decisions*. New York: Marcel-Dekker, 219-234, **1982**.
42. Halperin M, Lan KKG, Ware JH, Johnson NJ and DeMets DL. An aid to data monitoring in long-term clinical trials. *Controlled Clinical Trials*, 3:311-323, **1982**.
41. Greenhouse SW. Jerome Cornfield's contributions to epidemiology. *Biometrics Supplement: Current Topics in Epidemiology*, 33-45, **1982**.
40. Mantel N. Citation Classic: Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *Current Contents, Life Sciences*, 24:19, **1981**.
39. Lachin JM. Perceptions of the coordinating center: Foreword. *Controlled Clinical Trials*, 1:125-126, **1980**.
38. Greenhouse SW. Some epidemiologic issues for the 1980's. *American Journal of Epidemiology*, 112:269-273, **1980**.
37. Cornfield J, Rai K and Van Ryzin J. Procedures for assessing risk at low levels of exposure. *Archives of Toxicology, Supplement 3*:295-303, **1980**.
36. Mantel N. A miscellany of statistical and other considerations for clinical trials. *Controlled Clinical Trials*, 1:3-11, **1980**.
35. Lachin JM. Sample size considerations for clinical trials of potentially hepatotoxic drugs. In Davidson CS, Leevy CM, and Chamberlayne EC, editors, *Guidelines for Detection of Hepatotoxicity Due to Drugs and Chemicals, U.S. Department of H.E.W., National Institutes of Health, NIH Publication No. 79-313*, 119-130, **1979**.
34. Halperin M, Wu M, and Gordon T. Genesis and interpretation of differences in distribution of baseline characteristics between cases and non-cases in cohort studies. *Journal of Chronic Diseases*, 32:483-491, **1979**.
33. Cornfield J. Therapeutic and preventive trials. In Onesti G and Klimt CR editors, *Hypertension - Determinants, Complications, and Intervention*. New York: Gruen and Stratton, 451-454, **1979**.
32. Cornfield J, Carlborg FW and Van Ryzin J. Setting tolerances on the basis of mathematical treatment of dose-response data extrapolated to low doses. In Plaa GL and Duncan WAM, editors, *Proceedings of the First International Congress on Toxicology*. New York: Academic Press, 143-163, **1978**.

31. Mantel N. Correspondence re: Crump KS, Hoel DG, Langley CH, and Peto R. Fundamental carcinogenic processes and their implications for low-dose risk assessment, *Cancer Research*, 36:2973-2979, **1976**, and Guess H, Crump K and Peto R. Uncertainty estimates for low-dose-rate extrapolations of animal carcinogenicity data. *Cancer Research*, 37:3475-3483, 1977. *Cancer Research*, 38:1835-1838, **1978**.
30. Mantel N. Discussion of presentation by Hartley and Sielken on the estimation of "safe doses" in carcinogenic experiments. *Journal of Environmental Pathology and Toxicology*, 1:267-269, **1977**.
29. Mantel N. Aspects of the Hartley-Sielken approach for setting "safe doses" of carcinogens. *Origins of Human Cancer, Book C*: 1397-1401, **1977**.
28. Lachin JM. Informed consent in clinical investigations. *Biometrics*, 33:761-762, **1977**.
27. Mantel N and Blot WJ. Letter to the Editor: The influence of finite observation periods on familial and chronic disease epidemiology. *Journal of the National Cancer Institute*, 58:9-11, **1977**.
26. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. *Analysis and examples*. *British Journal of Cancer*, 35:1-39, **1977**.
25. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. *British Journal of Cancer*, 34:585-612, **1976**.
24. Cornfield J. Recent methodological contributions to clinical trials. *American Journal of Epidemiology*, 104:408-420, **1976**.
23. Kullback S and Cornfield J. An information theoretic contingency table analysis of the Dorn study of smoking and mortality. *Computers and Biomedical Research*, 9:409-437, **1976**.
22. Mantel N. Letter to the editor: Factors associated with perinatal and postperinatal mortality in Belfast 1962-1966: Statistical analysis gone awry. *Journal of Chronic Diseases*, 29:415-416, **1976**.
21. Mantel N. A personal perspective on statistical techniques for quasi-experiments. In Owens DB, editor, *On The History of Statistics and Probability*. New York:Marcel Dekker, 103-129, **1976**.
20. Mantel N. Tails of distributions. *The American Statistician*, 30:14-17, **1976**.
19. Mantel N and Blot WJ. Is Hodgkin's disease infectious? Discussion of an epidemiologic method used to impute that it is. *Journal of National Cancer Institute*, 56:413-414, **1976**.

18. Cornfield J. Design of clinical trials. In *The Research Status of Spinal Manipulative Therapy*. NINCDS Monograph No. 15. Washington: U.S. Department of Health, Education, and Welfare: 303-306, **1975**.
17. Cornfield J, Pipberger HV and Dunn RA. The program of the cooperative study of the Veterans Administration. *Giornale Italiano Di Cardiologia*, 5:256-261, **1975**.
16. Pipberger HV, McCaughan D, Littmann D, Pipberger HA, Cornfield J, Dunn RA, Batchlor CD and Berson AS. Clinical application of a second generation electrocardiographic computer program. *The American Journal of Cardiology*, 35:597-608, **1975**.
15. Schneiderman MA, Mantel N and Brown CC. From mouse to man—or how to get from the laboratory to Park Avenue and 59<sup>th</sup> street. *Annals of the NY Academy of Science*, 246:237-248, **1975**.
14. Mantel N. Evaluation du potentiel cancerogene. *Colloque International sur L'innocuite des medicaments: Mise au Point et Emploi de Medicaments Surs et Efficaces*, Canada: Ministere de la Sante Nationale et du Bien-etre social, 55-72, **1975**.
13. Mantel N. The assessment of carcinogenicity. *Proceedings of the International symposium on Drug Safety*. Canada: Department of National Health and Drug Welfare, 50-65, **1975**. **English translation of the above.**
12. Cornfield J. Correspondence. Baseline differences and the randomized clinical trial. *Clinical Pharmacology and Therapeutics*, 15:225, **1974**.
11. Pipberger HV and Cornfield J. Letter to the Editor. Evaluating computer ECG programs. *Circulation*, 50:1287-1288, **1974**.
10. Goldin A, Venditti JM and Mantel N. Combination chemotherapy: Basic considerations. In *Sartorelli AC and Johns DG, editors, Handbook of Experimental Pharmacology*. Berlin: Springer-Verlag, 411-448, **1974**.
9. Goldin A, Carter S and Mantel N. Evaluation of antineoplastic activity: Requirements of test systems. Sartorelli AC and Johns DG, editors, *Handbook of Experimental Pharmacology*, Berlin: Springer-Verlag, 38:12-32, **1974**.
8. Mantel N. Therapeutic synergism. *Cancer Chemotherapy Reports*, 4:147-149, **1974**.
7. Pipberger HV and Cornfield J. What ECG computer program to choose for clinical application. The need for consumer protection. *Circulation*, 47:918-920, **1973**.

6. Shaw LW, Cornfield J and Cole CM. Statistical problems in the design of clinical trials and interpretation of results. In Deutsch E, Lechner K, Brinkhous KM and Hinnom S, editors, *Thrombosis: Pathogenesis and Clinical Trials. Transactions of the Plenary Sessions, IV International Congress on Thrombosis and Haemostasis, Vienna, Austria. Stuttgart, New York: Schattauer Verlag: 191-202, 1973.*
5. Dunn RA, Pipberger HV and Cornfield J. The U. S. Veterans Administration ECG analysis system. In Zywiets C and Schneider B, editors, *Computer Application on ECG and VCG Analysis.* Amsterdam: North Holland: 142-153, **1973.**
4. Cornfield J, Dunn RA, Batchlor CD and Pipberger HV. Multigroup diagnosis of electrocardiograms. *Computers and Biomedical Research*, 6:97-120, **1973.**
3. Cornfield J. Approaches to assessment of the efficacy of surgical revascularization. *Bulletin of the New York Academy of Medicine*, 48:1126-1134, **1972.**
2. Haisty WK, Batchlor C, Cornfield J and Pipberger HV. Discriminant function analysis of RR intervals: An algorithm for on-line arrhythmia diagnosis. *Computers and Biomedical Research*, 5:247-255, **1972.**
1. Pipberger HV, Cornfield J and Dunn RA. Diagnosis of the electrocardiogram. In Jaquez, JA, editor, *Computer Diagnosis and Diagnostic Methods.* Springfield, Illinois: Charles C. Thomas: 355-373, **1972.**

## **CLINICAL TRIALS AND EPIDEMIOLOGIC METHODS – Books PUBLISHED**

1. Rosenberger, W and Lachin JM. Randomization in Clinical Trials: Theory and Practice. John Wiley and Sons, **2002.** (ISBN: 0-471-23626-8).

## **RESULTS OF MEDICAL INVESTIGATION**

### **ANGIOTENSIN CONVERTING ENZYME INHIBITION IN DIABETIC NEPHROPATHY (ACE)**

6. Rodby R, Rohde R, Evans J, Bain RP, Mulcahy WS, Lewis EJ and the Collaborative Study Group. The Study of the Effect of Intensity of Blood Pressure Management on the progression of type 1 diabetic nephropathy: Study design and baseline patient characteristics. *Journal of the American Society of Nephrology*, 5:1775-1781, **1995**.
5. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD and Lewis EJ, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. *Kidney International*, 46:1688-1693, **1994**.
4. Breyer JA, Hunsicker LG, Bain RP, Lewis EJ and the Collaborative Study Group. Angiotensin converting enzyme inhibition in diabetic nephropathy. *Kidney International*, 45:S156-S160, **1994**.
3. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. *The New England Journal of Medicine*, 329:1456-1462, **1993**.
2. Bain R, Rohde R, Hunsicker LG, McGill J, Korbin S, Lewis EJ and the Collaborative Study Group. A controlled clinical trial of angiotensin-converting enzyme inhibition in Type I diabetic nephropathy: Study design and patient characteristics. *Journal of the American Society of Nephrology*, 3:S97-S103, **1992**.
1. Lemann J, Bidani AK, Bain RP, Lewis EJ, Rohde RD and the Collaborative Study Group of the Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy. Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. *American Journal of Kidney Diseases*, 16:236-243, **1990**.

### **CENTER FOR CONSUMER HEALTH EDUCATION PROGRAM**

1. Vickery DM, Kalmer H, Lowry D, Constantine M, Wright E and Loren W. Effect of a self-care education program on medical visits. *Journal of the American Medical Association*, 250:2952-2956, **1983**.

## CENTER TO PROTECT WORKERS RIGHTS

1. Pollack ES and Ringen K. Risk of hospitalization for specific non-work-related conditions among laborers and their families. *American Journal of Industrial Medicine*, 23:417-425, **1993**.

## CHORIONIC VILLUS SAMPLING (CVS)

12. Jackson L and Zachary J. Early Prenatal Diagnostics. In Stengel-Rutkowski S, editor, *Proceedings of the Final Colloquium of the German Collaborative Study on "Prenatal Diagnostics on Chorionic Villi"*. Munich: Federal Ministry of Science and Technology, **1993**.
11. Smidt-Jensen S, Lind AM, Permin M, Zachary JM, Lundsteen C and Philip J. Cytogenetic analysis of 2928 CVS samples and 1075 amniocenteses from randomized studies. *Prenatal Diagnosis*, 13:723-740, **1993**.
10. Burton, B, Desposito F, Froster, U, Holmes LB, Holzgreve W, Jackson L, Lage J, Mahoney MJ, Mennuti M, Milner R, Olney R, Wilson RD, Zachary JM, de la Cruz F and Kaminetzky H. Report of National Institute of Child Health and Human Development Workshop on chorionic villus sampling and limb and other defects, October 20, 1992. *Teratology*, 48:7-13, **1993**.
9. Smidt-Jensen S, Permin M, Philip J, Lundsteen C, Zachary JM, Fowler SE and Gruning K. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. *The Lancet*, 340:1237-1244, **1992**.
8. Jackson LG, Zachary JM, Fowler SE, Desnick RJ, Golbus MS, Ledbetter DH, Mahoney MJ, Pergament E, Simpson JL, Black S, Wapner RJ and the U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. A randomized comparison of transcervical and transabdominal chorionic-villus sampling. *The New England Journal of Medicine*, 327:594-598, **1992**.
7. Desnick RJ, Schuette JL, Golbus MS, Jackson L, Lubs HA, Ledbetter DH, Mahoney MJ, Pergament E, Simpson JL, Zachary JM, Fowler SE, Rhoads GG and de la Cruz F. First-trimester biochemical and molecular diagnoses using chorionic villi: High accuracy in the U.S. collaborative study. *Prenatal Diagnosis*, 12:357-372, **1992**.

6. Golbus MS, Simpson JL, Fowler SE, de la Cruz F, Desnick RJ, Wapner R, Ledbetter DH, Lubs H, Mahoney MJ, Pergament E, Rhoads GG, Schulman JD and Zachary J. Risk factors associated with transcervical CVS losses. *Prenatal Diagnosis*, 12:373-376, **1992**.
5. Wapner RJ, Simpson JL, Golbus MS, Zachary JM, Ledbetter DH, Desnick RJ, Fowler SE, Jackson LG, Lubs H, Mahony RJ, Pergament E, Rhoads GG, Shulman JD and de la Cruz F. Chorionic mosaicism: Association with fetal loss but not with adverse perinatal outcome. *Prenatal Diagnosis*, 12:347-355, **1992**.
4. Ledbetter DH, Zachary JM, Simpson JL, Golbus MS, Pergament E, Jackson L, Mahoney MJ, Desnick RJ, Schulman J, Copeland KL, Verlinsky Y, Yang-Feng T, Schonberg SA, Babu A, Tharapel A, Dorfmann A, Lubs HA, Rhoads GG, Fowler SE and de la Cruz, F. Cytogenetic results from the U.S. collaborative study on CVS. *Prenatal Diagnosis*, 12:317-345, **1992**.
3. Mahoney MJ, for the USNICHD Collaborative CVS Study Group. Letter to the Editor. Limb abnormalities and chorionic villus sampling. *The Lancet*, 337:1422-1423, **1991**.
2. Ledbetter DH, Martin AO, Verlinsky Y, et al. Cytogenetic results of chorionic villus sampling: High success rate and diagnostic accuracy in the United States collaborative study. *American Journal of Obstetrics and Gynecology*, 162:495-501, **1990**.
1. Rhoads GG, Jackson LG, Schlesselman SE, et al. "The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. *The New England Journal of Medicine*, 320:609-617, **1989**.

## **CLINICAL STUDY OF INTERMITTENT POSITIVE PRESSURE BREATHING**

6. Tockman MS, Anthonisen NR, Wright EC and Donithan MG. The Intermittent Positive Pressure Breathing Trial Group and The Johns Hopkins Lung Project for the Early Detection of Lung Cancer. Airways obstruction and the risk for lung cancer. *Annals of Internal Medicine*, 106:512-518, **1987**.
5. Grant I, Prigatano GP, Heaton RK, McSweeney AJ, Wright EC and Adams KM. Progressive neuropsychologic impairment and hypoxemia: Relationship in Chronic Pulmonary Disease. *Archives of General Psychiatry*, 44:999-1006, **1987**.

4. Anthonisen NR, Wright EC, Hodgkin JE, and the IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. *American Review of Respiratory Disease*, 133:14-20, **1986**.
3. Prigatano GP, Wright EC and Levin D. Quality of life and its predictors in mildly hypoxemic chronic obstructive pulmonary disease. *Archives of Internal Medicine*, 144:1613-1619, **1984**.
2. The Intermittent Positive Pressure Breathing Trial Group. Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease: A clinical trial. (Written by Anthonisen NR, Wright EC and Krueger DE.) *Annals of Internal Medicine*, 99:612-620, **1983**.
1. Prigatano G, Parsons O, Wright E, Levin DC and Hawryluk, G. Neuropsychological test performance in mildly hypoxemic patients with chronic obstructive pulmonary disease. *Journal of Consulting and Clinical Psychology*, 51:108-116, **1983**.

## **DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)**

60. The Diabetes Control and Complications Trial Research Group. "Influence of Intensive Diabetes Treatment on Body Weight and Composition of Adults with Type 1 Diabetes in the Diabetes Control and Complications Trial." *Diabetes Care*, 24:1711-1721, **2001**.
59. The Diabetes Control and Complications Trial Research Group. "Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial." *Diabetes Care*, 23:1084-1091, **2000**.
58. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA and Brunzell JD. "Increased Small Dense LDL and Intermediate-Density Lipoprotein with Albuminuria in Type 1 Diabetes." *Diabetes Care*, 22.7: 1165-70, **1999**.
57. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary P, Lachin J, Genuth S and the DCCT Collagen Ancillary Study Group. "Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes: Relevance of glycated collagen products versus HbA<sub>1c</sub> as markers of diabetic complications." *Diabetes*, 48:870-880, **1999**.
56. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia*, 41:416-423, **1998**.

55. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual Beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: A randomized, controlled trial. *Annals of Internal Medicine*, 128:517-523, **1998**.
54. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Archives of Ophthalmology*, 116:874-886, **1998**.
53. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA and Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. *Journal of the American Medical Association*, 280:140-146, **1998**.
52. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. *Diabetes*, 46:1829-1839, **1997**.
51. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trail. *Diabetes*, 46:271-286, **1997**.
50. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. *Diabetes*, 45:1289-1298, **1996**.
49. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. *Journal of the American Medical Association*, 276:1409-1415, **1996**.
48. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. *American Journal of Obstetrics and Gynecology*, 174:1343-1353, **1996**.
47. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. *Diabetes Care*, 19:195-203, **1996**.
46. The Diabetes Control and Complications Trial Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. *Annals of Internal Medicine*, 124:379-388, **1996**.
45. Leiter LA, and the Diabetes Control and Complications Trial Research Group. "Use of Bioelectrical Impedance Analysis Measurements in Patients with Diabetes." *American Journal of Clinical Nutrition*, 64 supplement, 515S-518S, **1996**.

44. The Diabetes Control and Complications Trial Research Group. "Effect of Intensive Diabetes Treatment on Nerve Conduction in the Diabetes Control and Complications Trial." *Annals of Neurology*, 38:869-880, **1995**.
43. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. *Diabetes Care*, 18:1415-1427, **1995**.
42. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. *Diabetes Care*, 18:1468-1478, **1995**.
41. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, and Brunzell JD. Levels of lipoprotein (a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. *Diabetes*, 44:1218-1226, **1995**.
40. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA<sub>1c</sub>) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. *Diabetes*, 44:968-983, **1995**.
39. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. *The American Journal of Cardiology*, 75:894-903, **1995**.
38. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. *Kidney International*, 47:1703-1720, **1995**.
37. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. *Annals of Internal Medicine*, 122:561-568, **1995**.
36. The Diabetes Control and Complications Trial Research Group; Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Archives of Internal Medicine*, 155:745-754, **1995**.
35. The Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. *Ophthalmology*, 102:647-661, **1995**.
34. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complication Trial. *Archives of Ophthalmology*, 113:36-51, **1995**.

33. The Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. *Diabetes Care*, 18:361-376, **1995**.
32. The Diabetes Control and Complications Trial Research Group. Psychological aspects of the DCCT. In *The Technology of Diabetes Care: Converging Medical and Psychosocial Perspectives*, 122-139, **1994**.
31. Leiter LA, Lukaski HC, Kenny DJ, Barnie A, Camelon K, Ferguson RS, MacLean S, Simkins S, Zinman B and Cleary PA for the DCCT Research Group. The use of Bioelectrical Impedance Analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT). *International Journal of Obesity*, 18:829-835, **1994**.
30. Schmidt LE, Cox MS, Buzzard IM, and Cleary PA, for the DCCT Research Group. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. *Journal of the American Dietetic Association*, 94:1392-1397, **1994**.
29. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. *The Journal of Pediatrics*, 125:177-188, **1994**.
28. The DCCT Research Group. A screening algorithm to identify clinically significant changes in neuropsychological functions in the Diabetes Control and Complications Trial. *Journal of Clinical and Experimental Neuropsychology*, 16:303-316, **1994**.
27. The DCCT Research Group. The impact of the trial coordinator in the Diabetes Control and Complications Trial. *Diabetes Educator*, 19:509-512, **1993**.
26. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, and Steffes MW, for the Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Glomerular filtration rate measurements in clinical trials. *Journal of the American Society of Nephrology*, 4:1159-1171, **1993**.
25. The DCCT Research Group. "Nutrition Interventions for Intensive Therapy in the Diabetes Control and Complications Trial." *The Journal of the American Dietetic Association*, 93:768-772, **1993**.
24. The DCCT Research Group. Expanded role of the dietitian in the Diabetes Control and Complications Trial: Implications for clinical practice. *The Journal of the American Dietetic Association*, 93:758-767, **1993**.

23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *The New England Journal of Medicine*, 329:977-986, **1993**.
22. The Diabetes Control and Complications Trial Research Group. Baseline analysis of renal function in the Diabetes Control and Complications Trial. *Kidney International*, 43:668-674, **1993**.
21. The DCCT Research Group. Lipid and lipoprotein levels in patients with IDDM: Diabetes Control and Complications Trial Experience. *Diabetes Care*, 15:886-894, **1992**.
20. Ryan CM, Adams KA, Heaton RK, Grant I, Jacobson AM and the DCCT Research Group. Neurobehavioral assessment of medical patients in clinical trials: The DCCT Experience. In Mohr E and Brouwers P, editors, *Handbook of Clinical Trials; The Neurobehavioral Approach*. Amsterdam/Lisse: Swets and Zeitlinger, 215-240, **1991**.
19. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. *The American Journal of Medicine* 90:450-459, **1991**.
18. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Update. *Diabetes Care*, 13:427-433, **1990**.
17. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): The trial coordinator perspective. *Diabetes Educator*, 15:236-241, **1989**.
16. The DCCT Research Group. The DCCT: Will it answer the questions? In Larkin R, Zimmer P, Chisolm D, editors, *Diabetes 1988*. Amsterdam: Elsevier: 847-855, **1989**.
15. Siebert C for The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): Results of the feasibility study and design of the full-scale clinical trial. In Laron Z, Kamp M, editors, *Pediatric and Adolescent Endocrinology*. Tel Aviv: Basel, Karger:18:15-21, **1989**.
14. The DCCT Research Group. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. *Controlled Clinical Trials*, 10:83-96, **1989**.
13. The DCCT Research Group. Update. *Diabetes Spectrum*, 1:187-190, **1988**.
12. The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the Diabetes Control and Complications Trial (DCCT). *Diabetes Care*, 11:725-732, **1988**.
11. The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. *Diabetes Care*, 11:567-573, **1988**.

10. Schumer M, Burton G, Burton C, Crum D, Pfeifer MA, and The DCCT Study Group. Diabetic autonomic neuropathy-Part I. Autonomic nervous system data analysis by a computerized central unit in a multicenter trial. *The American Journal of Medicine*, 85, supplement 5A: 137-143, **1988**.
9. Hanssen KF, The DCCT Research Group, and Brunetti P. Is there a need for a continuation of the DCCT in 1988? *Diabetes Nutrition and Metabolism*, 1:151-159, **1988**.
8. The DCCT Research Group. Factors in development of diabetic neuropathy: Baseline analysis of neuropathy in feasibility phase of the Diabetes Control and Complications Trial (DCCT). *Diabetes*, 37:476-481, **1988**.
7. The DCCT Research Group. Are continuing studies of metabolic control and microvascular complications in insulin-dependent diabetes mellitus justified? The Diabetes Control and Complications Trial. *The New England Journal of Medicine*, 318:246-250, **1988**.
6. The Diabetes Control and Complications Trial Research Group. Color photography vs. fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complications Trial. *Archives of Ophthalmology*, 105:1344-1351, **1987**.
5. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. *Diabetes Care*, 10:1-19, **1987**.
4. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: A multicenter study. *Clinical Chemistry*, 33:2267-2271, **1987**.
3. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual Beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). *Journal of Clinical Endocrinology and Metabolism*, 65:30-36, **1987**.
2. The DCCT Research Group. Treatment regimen design in the Diabetes Control and Complications Trial (DCCT). *Transplantation Proceedings*, 18:1678-1680, **1986**.
1. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): Design and methodologic considerations for the feasibility phase. *Diabetes*, 35:530-545, **1986**.

## DIABETES PREVENTION PROGRAM (DPP)

59. Ma Y, Temprosa M, Fowler S, Prineas R, Montez M, Brown-Friday J, Carrion-Petersen M, Whittington T, for The Diabetes Prevention Program Research Group. "Evaluating the Accuracy of an Aneroid Sphygmomanometer in a Clinical Trial Setting." *American Journal of Hypertension*, Mar 22(2):263-266, **2009**.
58. Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC for The Diabetes Prevention Program Research Group. "The associate of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program." *Journal of Clinical Endocrinology and Metabolism*. Feb;94(2):449-455, **2009**.
57. Mather K, Funahashi T, Matsuzawa Y, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein B, Goldberg R for the DPP Research Group. "Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program." *Diabetes*. Apr;57:980-6, **2008**. PMID: PMC2529455.
56. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC for the Diabetes Prevention Program Research Group. "Elevated depression symptoms, antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program." *Diabetes Care*. Mar;31(3):420-6, **2008**. PMID: PMC2373986.
55. Bray GA, Jablonski KA, Fujimoto WF, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX for the Diabetes Prevention Program Research Group. "Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program." *American Journal of Clinical Nutrition*. May;87(5):1212-8, **2008**. PMID: PMC2517222.
54. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM for the Diabetes Prevention Program Research Group. "The prevention of type 2 diabetes." *Nature Clinical Practice. Endocrinology and Metabolism*. Jul;4(7):382-93, **2008**. PMID: PMC2573045.
53. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC for the Diabetes Prevention Program Research Group. "Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program." *Diabetes*. Sept;57:2503-10, **2008** .

52. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E for the Diabetes Prevention Program Research Group. "Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program." *Diabetes Care*. July;31(7):1416-21, **2008**. PMID: PMC2453677.
51. Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SM, Hamman RF, Hoskin MA, Knowler WC, Ma Y for the Diabetes Prevention Program Research Group. "First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes." *International Journal of Obesity*. August 19; **2008**. PMID: PMC2574826.
50. Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan V, Barrett-Connor E, Watson K, Knowler WC, Horton ES for the Diabetes Prevention Program Research Group. "Value of urinary albumin creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals." *Diabetes Care*. Sept;31:2344-8, **2008**.
49. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; The Diabetes Prevention Program Research Group. "Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions." *Journal of Clinical Endocrinology and Metabolism*. 2008 Dec;93(12):4646-7 **2008**.
48. Hoerger TJ, Hicks KA, Sorenson SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Englegau MM. "Cost-effectiveness of Screening for Prediabetes Among Overweight U.S. Adults." *Diabetes Care*. 30:2874-2879, **2007**.
47. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E for the Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care*. Oct;30(10):2453-7, **2007**. PMID: PMC2373980.
46. Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC for the Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. *Diabetologia*. Dec;50(12):2451-60, **2007**. PMID: PMC2453532.

45. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, Franks, PW, Altshuler D, Knowler WC for the Diabetes Prevention Program. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. *Diabetologia*. Dec 4;51:451-7, **2007**. PMID: PMC2483955.
44. Nathan D, Chew E, Christophi C, Davis M, Fowler S, Goldstein B, Hamman R, Hubbard L, Knowler W, and Molitch M. (The Diabetes Prevention Program Research Group). "The Prevalence of Retinopathy in Impaired Glucose Tolerance and Recent-Onset Diabetes in the Diabetes Prevention Program." *Diabetic Medicine*, 24.2:137-44, **2007**. PMID: PMC2267935
43. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, Pi-Sunyer FX for the Diabetes Prevention Program Research Group. "Body Size and Shape Changes and the Risk of Diabetes in the Diabetes Prevention Program (DPP)." *Diabetes*, 56:1680-85, **2007**. PMID: PMC2528279.
42. Lachin J, Christophi C, Edelstein S, Ehrman D, Fowler S, Hamman R, Kahn S, Knowler W, and Nathan D. "Factors Associated with Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program (DPP)." *Diabetes*, 56.4: 1153-59, **2007**. PMID: PMC2533728.
41. Florez JC, KA Jablonski, MW Sun, N Bayley, SE Kahn, H Shamon, RF Hamman, WC Knowler, DM Nathan, D Altshuler for the Diabetes Prevention Program Research Group. "Effects of the Type 2 Diabetes-Associated PPARG P12A Polymorphism on Progression to Diabetes and Response to Troglitazone." *Journal of Clinical Endocrinology and Metabolism*, 92: 1502-09, **2007**. PMID: PMC2267936.
40. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan CM and Altshuler D for the Diabetes Prevention Program Research Group. "Type 2 Diabetes-Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program." *Diabetes*, 56:531-6, **2007**. PMID: PMC2267937.
39. The Diabetes Prevention Program Research Group. "Relationship of Body Size and Shape to the Development of Diabetes in the Diabetes Prevention Program." *Obesity*, 14.11: 2107-17, **2006**.

38. The Diabetes Prevention Program Research Group. "The Influence of Age on the Effects of Lifestyle Modification and Metformin in Prevention of Diabetes." *Journal of Gerontology Series A: Biological Sciences and Medical Sciences*, 61:1075-81, **2006**.
37. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J, for the Diabetes Prevention Program Research Group. "Adherence to Preventive Medications: Predictors and Outcomes in the Diabetes Prevention Program." *Diabetes Care*, 29.9:1997-2002, **2006**.
36. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J, for the Diabetes Prevention Program Research Group. "Effect of Weight Loss with Lifestyle Intervention on Risk of Diabetes." *Diabetes Care*, 29.9:2102-7, **2006**.
35. Ratner R for the Diabetes Prevention Program Research Group. "An Update on the Diabetes Prevention Program." *Endocrine Practice*, 12 Suppl 1:20-4, **2006**.
34. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG. "Physical activity in individuals at risk for diabetes: Diabetes Prevention Program." *Medicine & Science in Sports & Exercise*, 38.5:826-32, **2006**.
33. Delahanty LM, Conroy MB, Nathan DM, and the Diabetes Prevention Program Research Group. "Psychological predictors of physical activity in the Diabetes Prevention Program." *Journal of the American Dietetic Association*, 106.5:698-705, **2006**.
32. Florez J, Jablonski K, Bayley N, Pollin T, de Bakker P, Kitabchi A, Shuldiner A, Knowler W, Nathan D and Altshuler D for the Diabetes Prevention Program Research Group. "TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program." *New England Journal of Medicine*, 355:241-50, **2006**.
31. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME. "The Association Among Autonomic Nervous System Function, Incident Diabetes, and Intervention Arm in the Diabetes Prevention Program." *Diabetes Care*, 29(4):914-9, **2006**.
30. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y, Vittinghoff E, Kanaya AM. "Lifestyle Intervention Is Associated with Lower Prevalence of Urinary Incontinence: The Diabetes Prevention Program." *Diabetes Care*, 29(2):385-90, **2006**.

29. Hoskin M, Begay S, Bolin P, Hermes J, Ingraham L, Killean T, Nelson J, Percy C, Scurlock N, Shovestull LE, Tomchee C, the Diabetes Prevention Program and Action for Health in Diabetes (Look AHEAD) research groups. "Providing lifestyle interventions in American Indian communities." *Obesity Management Journal*, 1.6:251-5, **2005**.
28. The DPP Research Group. "Lipid, Lipoproteins, C-Reactive Protein and Hemostatic Factors at Baseline in the Diabetes Prevention Program." *Diabetes Care*, 28.10:2472-2479, **2005**.
27. The DPP Research Group. "Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin." *Diabetes Care*, 54.8:2404-2414, **2005**.
26. Diabetes Prevention Program Research Group. "Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants with Impaired Glucose Tolerance." *Diabetes Care*, 54.5:1566-1572, **2005**.
25. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group. "The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial." *Annals of Internal Medicine*, 142.8:611-619, **2005**.
24. The Diabetes Prevention Program Research Group. "Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program." *Diabetes Care*, 54.4:1150-1156, **2005**.
23. Diabetes Prevention Program Research Group. "Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular (CVD) Risk Factors in the Diabetes Prevention Program." *Diabetes Care*, 28.4:888-894, **2005**.
22. Diabetes Prevention Program Research Group. "Depression Symptoms and Antidepressant Medicine Use in Diabetes Prevention Program (DPP) Participants." *Diabetes Care*, 28.4:830-837, **2005**.
21. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE, Diabetes Prevention Program Research Group. "The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance." *Annals of Internal Medicine*, 142.5:323-332, **2005**.
20. The DPP Research Group. "Strategies to Identify Adults at High Risk for Type 2 Diabetes." *Diabetes Care*, 28.1:138-144, **2005**.
19. Mayer-Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, Hoskin M, Kriska AM, Bray G and the Diabetes Prevention Program Research Group. "Dietary intake in the Diabetes Prevention Program cohort: Baseline and 1-year post-randomization." *Annals of Epidemiology*, 14.10:763-72, **2004**.

18. The DPP Research Group. "Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants." *Obesity Research*, 12.9:1426-1434, **2004**.
17. Molitch M, Fujimoto W, Hamman R, Knowler W for the Diabetes Prevention Program Research Group. "The Diabetes Prevention Program and its global implications (Singapore paper)." *Journal of the American Society of Nephrology*, 14.7 S2:S103-7, **2003**.
16. Molitch M. for the Diabetes Research Group. "Response to Scheen and Buchaan." *Diabetes Care*, 26.9:2702-2703, **2003**.
15. The Diabetes Prevention Program Research Group. "Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes." *Diabetes Care*, 26.9:2518-2523, **2003**.
14. The Diabetes Prevention Program Research Group. "Effects of Withdrawal from Metformin on the Development of Diabetes in the Diabetes Prevention Program." *Diabetes Care*, 26.4:977-980, **2003**.
13. The Diabetes Prevention Program Research Group. "Costs Associated with the Primary Preventions of Type 2 Diabetes Mellitus in the Diabetes Prevention Program." *Diabetes Care*, 26.1:36-47, **2003**.
12. The DPP Research Group. "The Diabetes Prevention Program (DPP): Description of lifestyle intervention." *Diabetes Care*, 25.12:2165-2171, **2002**.
11. Wylie-RJ, Delahanty L. "An Integral Role of the Dietitian: Implications of the Diabetes Prevention Program". *Journal of the American Dietetic Association*, 102(8):1065-8, **2002**.
10. Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM, and the DPP Research Group. "Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP)". *Diabetes Care*, 25(11):1992-8, **2002**.
9. The Diabetes Prevention Program Research Group. "Hypertension, Insulin, Proinsulin in Participants with Impaired Glucose Tolerance." *Hypertension*, 40:679-686, **2002**.
8. The DPP Research Group. "Response to Bo-abbas, Brousseau, Louria, Benjamin, et al." *New England Journal of Medicine*, 346:1829-1830, **2002**.
7. DPP Research Group. "Reduction in the incidence of Type 2 Diabetes with lifestyle intervention or Metformin." *The New England Journal of Medicine*, 346:393-403, **2002**.
6. DPP Research Group. "The Diabetes Prevention Program: recruitment methods and results." *Controlled Clinical Trials*, 23:157-171, **2002**.

5. DPP Research Group. "The Diabetes Prevention Program: Baseline characteristics of the randomized cohort." *Diabetes Care*, 23:1619-1629, **2000**.
4. Fujimoto WY. "Background and Recruitment Data for the U.S. Diabetes Prevention Program." *Diabetes Care*, 23 (Suppl. 2):B11-B13, **2000**.
3. The DPP Research Group. "Response to Adler, Turner, Singer et al." *Diabetes Care*, 22.10:1757-1758, **1999**.
2. DPP Research Group. "The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes." *Diabetes Care*, 22.4:623-634, **1999**.
1. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR and Hamman RF. "Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies." *Diabetes*, 46.4:701-710, **1997**.

## **DICHLOROACETATE-LACTIC ACIDOSIS STUDY GROUP**

2. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan C, Harman EM, Henderson GN, Jenkinson S, Lachin JM, Lorenz A, Schneider SH, Siegel JH, Summer WR, Thompson D, Wolfe CL, Zorovich B and the DCA-Lactic Acidosis Study Group. Natural history and course of acquired lactic acidosis in adults. *The American Journal of Medicine*, 97:47-54, **1994**.
1. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan CA, Harman EM, Henderson GN, Jenkinson S, Lachin JM, Lorenz A, Schneider SH, Siegel JH, Summer WR, Thompson D, Wolfe CL, Zorovich B and the Dichloroacetate-Lactic Acidosis Study Group. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. *The New England Journal of Medicine*, 327:1564-1569, **1992**.

**RANDOMIZED TRIAL OF 11-14 WEEK AMNIOCENTESIS AND TRANSABDOMINAL CVS (EATA) – FIRST TRIMESTER MATERNAL SERUM BIOCHEMISTRY AND FETAL NUCHAL TRANSLUCENCY SCREENING ANCILLARY STUDY (BUN)**

8. Bahado-Singh RO, Wapner R, Thom E, Zachary J, Platt L, Mahoney MJ, Johnson A, Silver RK, Pergament E, Filkins K, Hogge WA, Wilson RD, Jackson LG. “First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening Study Group. Elevated first-trimester nuchal translucency increases the risk of congenital heart defects.” *American Journal of Obstetrics and Gynecology*, 192:1357-61, **2005**
7. Silver RK, Wilson RD, Philip J, Thom EA, Zachary JM, Mohide P, Mahoney MJ, Simpson JL, Platt LD, Pergament E, Hershey D, Filkins K, Johnson A, Wapner RJ, Jackson LG, NICHD EATA Trial Group. “Late first-trimester placental disruption and subsequent gestational hypertension/preeclampsia.” *Obstetrics and Gynecology*, 105:587-92, **2005**.
6. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R for the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. “Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.” *American Journal of Obstetrics and Gynecology*, 191:1452-8, **2004**.
5. Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, Simpson JL, Silver RK, Snijders RJ, Goetzl L, Pergament E, Filkins K, Mahoney MJ, Hogge WA, Wilson RD, Mohide P, Hershey D, MacGregor S, Bahado-Singh R, Jackson LG, Wapner R, the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. “Sequential pathways of testing after first-trimester screening for trisomy 21.” *Obstetrics and Gynecology*, 104:661-6, **2004**.
4. Goetzl L, Kranzt D, Simpson JL, Silver RK, Zachary JM, Pergament E, Platt LD, Mahoney MJ, Wapner RJ and BUN Study Group. “Pregnancy-Associated Plasma Protein A, Free Beta-hCG, Nuchal Translucency, and Risk of Pregnancy Loss.” *Obstetrics and Gynecology*, 104.1: 30-36, **2004**.

3. Philip J, Silver RK, Wilson RD, Thom EA, Zachary JM, Mohide P, Mahoney MJ, Simpson JL, Platt LD, Pergament E, Hershey D, Filkins K, Johnson A, Shulman LP, Bang J, MacGregor S, Smith JR, Shaw D, Wapner RJ, Jackson LG and the NICHD EATA Trial Group. "Late First-Trimester Invasive Prenatal Diagnosis: Results of an International Randomized Trial." *Obstetrics and Gynecology*, 103.6: 1164-1173, **2004**.
2. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson D, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T and Jackson L for the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. "First-Trimester Screening for Trisomies 21 and 18." *New England Journal of Medicine*, 349: 1405-13, **2003**.
1. Snijders RJM, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, Sabbagha RE, Filkins K, Silver RK, Hogge WA, Ginsberg NA, Beverly S, Morgan P, Blum K, Chilis P, Hill LM, Hecker J, Wapner J and the BUN Study Group. "First-Trimester Trisomy Screening: Nuchal Translucency Measurement Training and Quality Assurance to Correct and Unify Technique." *Ultrasound in Obstetrics and Gynecology*, 19: 353-59, **2002**.

## **THE EFFECTS OF MATERNAL LIFESTYLE ON INFANT OUTCOMES (EMLI)**

2. Bauer CR, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, Smeriglio VL, Finnegan LP, Maza PL, and Verter J. The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. *American Journal of Obstetrics and Gynecology*, 186: 487-495, **2002**.
1. Lester BM, ElSohly M, Wright LL, Smeriglio VL, Verter J, Bauer CR, Shankaran S, Bada HS, Walls HC, Huestis MA, Finnegan LP, and Maza PL. The Maternal Lifestyle Study: Drug Use by Meconium Toxicology and Maternal Self-Report. *Pediatrics*, 107: 309-317, **2001**.

## EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)

42. Nathan DM, Zinman B, Cleary PA, Backlund JYC, Genuth S, Miller R, Orchard TJ, "Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' Duration." *Arch Intern Med* 169:1307-1316, **2009**
41. Chaturvedi N. "Metabolic Memory in the Autonomic Neuropathy of Diabetes: Implications for Pathogenesis and Patient Care." 119:2865-2867, **2009**
40. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin, JM, Herman WH, for the DCCT/EDIC Research Group. "Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus." *Circulation Journal of the American Heart Association*, 2887-2893, 1-4, **2009**
39. Pezzolesi MG, Poznik D, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DPK, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, the DCCT/EDIC Research Group, Doria A, Rogus JJ, Rich SS, Warram JH, and Krolewski AS. "Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes." *Diabetes*, 58:1403-1410, **2009**
38. Penson DF, Wessells H, Cleary P, Rutledge BN, and The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Sexual Dysfunction and Symptom Impact in Men with Long-Standing Type 1 Diabetes in the DCCT/EDIC Cohort." **2009**
37. Sarma AV, Kanaya A, Nyberg LM, Kusek JW, Vittinghoff E, Rutledge B, Cleary PA, Gatcomb P, Brown JS for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Risk Factors for Urinary Incontinence Among Women with Type 1 Diabetes: Findings From the Epidemiology of Diabetes Interventions and Complications Study." *Urology* 73:1203-1209, **2009**
36. Enzlin P, Rosen R, Wiegel M, Brown J, Wessells, Gatcomb P, Rutledge B, Chan KL, Cleary PA, the DCCT/EDIC Research Group. "Sexual Dysfunction in Women with Type 1 Diabetes." *Diabetes Care* 32:780-785, **2009**

35. Van Den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, McVary KT, Wessells H, for the DCCT/EDIC Research Group. "Effect of Intensive Glycemic Control and Diabetes Complications on Lower Urinary Tract Symptoms in Men with Type 1 Diabetes." *Diabetes Care*, 32:664-670, **2009**
34. Sarma AV, Kanaya AM, Nyberg LM, Kusek JW, Vittinghoff E, Rutledge B, Cleary PA, Gatcomb P, and Brown JS for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Urinary Incontinence Among Women with Type 1 Diabetes – How Common is it?" *The Journal of Urology*, 181: 1224-1230, **2009**
33. Czaja CA, Rutledge BN, Cleary PA, Chan K, Stapleton AE, Stamm WE, for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Urinary Tract Infections in Women with Type 1 Diabetes Mellitus: Survey of Female Participants in the Epidemiology of Diabetes Interventions and Complications Study Cohort." *The Journal of Urology*, 181:1129-1135, **2009**
32. Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler DJ for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. "Association of Diet with Glycated Hemoglobin During Intensive Treatment of Type 1 Diabetes in the Diabetes Control and Complications Trial." *American Journal of Clinical Nutrition*, 89:518-524, **2009**
31. Deeb SS, Brunzell JD., "The Role of the PGC1 & Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy." *PPAR Research*, 2-7, **2009**
30. Grant SFA, Qu HQ, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Skraban R, Imielinski M, Chiavacci RM, Grundmeier RW, Stanley CA, Kirsch SE, Waggott D, Paterson AD, Monos DS, the DCCT/EDIC Research Group, Polychronakos C, Hakonarson H. "Follow-up Analysis of Genome-wide Association Data Identifies Novel Loci for Type 1 Diabetes." *Diabetes*, 58:290-295, **2009**
29. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM, "Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus", *Arch Ophthalmol*, 126:1707-1715, **2008**

28. Grant SFA, Qu HQ, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Skraban R, Imielinski M, Chiavacci RM, Grundmeier RW, Stanley CA, Kirsch SE, Waggott D, Paterson AD, and the DCCT/EDIC Research Group, Monos DS, Polychronakos C, Hakonarson H, "Follow up Analysis of Genome-wide Association Data Identifies Novel Loci for Type 1 Diabetes" *Diabetes* **2008**
27. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G, and the DCCT/EDIC Study Group. "Risk Factors related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and their Relationship with Nephropathy and Macrovascular Complications" *Diabetes Care*, 2-14, **2008**
26. Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, Ho M, McKnight AJ, Maxwell AP, Savage DA, Kidd KK, Kidd JR, Speed WC, Orchard TJ, Miller RG, Sun L, Bull SB, Paterson AD, and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants are Associated with the Development and Progression of Diabetic Nephropathy," *Diabetes*, 57:218-228, **2008**
25. Musen G, Jacobson A, Ryan C, Cleary P, Waberski B, Weinger K, Dahms W, Bayless M, Silver N, Harth J, White N, and the DCCT/EDIC Research Group. "The Impact of Diabetes and its Treatments on Cognitive Function among Adolescents Who Participated in the DCCT." *Diabetes Care*, **2008**.
24. De Boer I, Kestenbaum B, Rue T, Steffes M, Cleary P, Molitch M, Lachin J, Weiss N, Brunzell J. "Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus." *Arch Intern Med*, 168:1867-1873, **2008**.
23. Lachin J, Genuth S, Nathan D, Zinman B, Rutledge B. "Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial – Revisited." *Diabetes*, 57:995-1001, **2008**.
22. De Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, Steffes MW, Weiss NS, Brunzell JD, for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study Research Group. "Central Obesity, Incident Microalbuminuria, and Change in Creatinine Clearance in the Epidemiology of Diabetes Interventions and Complications Study." *Journal of the American Society of Nephrology*, 18:235-243, **2007**

21. Al-Kateb H, Boright A, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bhupinder B, Liu M, Bucks J, Arends V, Steffes M, Cleary P, Sun W, Lachin J, Thorner P, Ho M, McKnight AJ, Maxwell AP, Savage D, Kidd K, Kidd J, Speed W, Orchard T, Miller R, Sun L, Bull S, Paterson A, and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants are Associated with the Development and Progression of Diabetic Nephropathy." *Diabetes*, 57:218-228, **2007**.
20. Carter R, Lacklan D, Cleary P, Yim E, Lopes-Virella M, Gilbert G, Orchard T. "Intensive Treatment of Diabetes is Associated with a Reduced Rate of Peripheral Arterial Calcification in the Diabetes Control and Complications Trial." *Diabetes Care*, 30:2646-2648, **2007**.
19. Albers J, Herman W, Pop-Busui R, Martin C, Cleary P, Waberski B. "Subclinical Neuropathy Among Diabetes Control and Complications Trial Participants Without Diagnosable Neuropathy at Trial Completion." *Diabetes Care*, 30:2613-2618, **2007**.
18. Sibley S, De Boer I, Steffes M, Brunzell J, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Study Group. "Intra-Abdominal Fat and Elevated Urine Albumin Excretion in Men with Type 1 Diabetes." *Diabetes Care*, 30:1898-1900, **2007**.
17. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull S, Boright AP, Paterson AD for the DCCT/EDIC Research Group. "Multiple Variants in Vascular Endothelial Growth Factor (VEGFA) Are Risk Factors for Time to Severe Retinopathy in Type 1 Diabetes." *Diabetes*, 56:2161-2168, **2007**.
16. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS, for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study." *Diabetes Care*, 30.8:2107-2112, **2007**.
15. Lachin JM, Genuth S, Nathan DM and Rutledge B. "The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial." *Diabetes*, 56.7: 1913-21, **2007**.

14. Jacobson AM, Ryan CM, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Silvers N, Harth J, Munsen G, The DCCT/EDIC Research Group. "Long-Term Effect of Diabetes and Its Treatment on Cognitive Function." *The New England Journal of Medicine*, 356.18:1842-52, **2007**.
13. Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee, D, Aston CE, Orchard TJ, Silvers N, Peng Y.G, McKnight JA, Baynes JW, Lyons TJ, The DCCT/EDIC Research Group. "Advanced Glycation End-Products and Methionine Sulphoxide in Skin Collagen of Patients with Type 1 Diabetes." *Diabetologia*, 49:2488-2498, **2006**.
12. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL and the DCCT/EDIC Research Group. "Neuropathy Among the Diabetes Control and Complication Trial Cohort 8 Years After Trial Completion." *Diabetes Care*, 29.2: 340-4, **2006**.
11. Cleary PA, Orchard TA, Genuth S, Wong ND, Detrano R, Backlund JC, Zinman B, Jacobson A, Sun W, Lachin JM, Nathan DM, for the DCCT/EDIC Research Group. "The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study." *Diabetes*, 55:3556-3565, **2006**.
10. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, for the DCCT Skin Collagen Ancillary Study Group. "Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants with Type 1 Diabetes." *Diabetes*, 54:3103-3111, **2005**.
9. Steffes M, Cleary P, Goldstein R, Little H, Wiedmeyer H M, Rohlfing C, England J, Bucksa J, Norwicki M, and the DCCT/EDIC Research Group. "Hemoglobin (HbA1c) Measurements Over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study." *Clinical Chemistry*, 51:753-758, **2005**.
8. Steffes M, Molitch M, Chavers B, Cleary P, Lachin J, Genuth S, and Nathan D for the DCCT/EDIC Research Group. "Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on the Development and Progression of Diabetic Nephropathy in Epidemiology of Diabetes Interventions and Complications (EDIC) Study." *Journal of the American Medical Association*, 290.16:2159-67, **2003**.

7. Nathan DM, Lachin JM, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, and Genuth SM for The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus." *The New England Journal of Medicine*, 348.23:2294-2303. **2003**.
6. Lipps J, Lorenzi G, Genuth S, Nathan D, Davis M, Lachin J, and Cleary P for the DCCT/EDIC Research Group. "The Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus." *Journal of the American Medical Association*, 287: 2563-2569, **2002**.
5. White N, Cleary P, Dahms W, Goldstein D, Malone J, and Tamborlane W for the DCCT/EDIC Research Group. "Beneficial Effects of Intensive Therapy of Diabetes During Adolescence: Outcomes After the Conclusion of the Diabetes Control and Complications Trial (DCCT)." *Journal of Pediatrics*, 139: 804-812, **2001**.
4. Lachin J, Genuth S, Nathan D, Davis M, Cleary P for the EDIC Research Group. "Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years After a Trial of Intensive Therapy." *The New England Journal of Medicine*, 342: 381-389, **2000**.
3. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA and Brunzell JD. "Increased Small Dense LDL and Intermediate-Density Lipoprotein with Albuminuria in Type 1 Diabetes." *Diabetes Care*, 22.7:1165-1170, **1999**.
2. Barnie A, Cleary P, Genuth S, Martin C, Mayfield R, Tamborlane W, Wesche J, and Shamoon H for the EDIC Research Group. "Epidemiology of Diabetes interventions and Complications (EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort." *Diabetes Care*, 22:99-111, **1999**.
1. Zinman B, Cleary P, O'Leary D, and Orchard T for the EDIC Research Group. "The Effect of Intensive Diabetes Treatment on Carotid Artery Wall Thickness in the Epidemiology of Diabetes Interventions and Complications (EDIC)." *Diabetes*, 48:383-390, **1999**.

**PPG Publications (Under EDIC)**

7. Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH, and the DCCT/EDIC Study Group. "Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type-1 Diabetes." *Diabetes*, 52.5: 1215-21, **2003**.

6. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT and the DCCT/EDIC Study Group. "Fibrinogen is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of Plasma Fibrinogen and Fibrinogen Gene Polymorphism in the DCCT/EDIC Cohort." *Diabetes Care*, 26.5: 1439-48, **2003**.
5. Jenkins AJ, Lyons TJ, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, and the DCCT/EDIC Research Group. "NMR Analysis of Lipoprotein Subclasses in the EDIC Cohort: Associations with Gender and Glycemia." *Diabetes Care*, 26(3): 810-18, **2003**.
4. Jenkins AJ, Lyons TJ, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R, and the DCCT/EDIC Research Group. "Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with Gender and Glycemia." *Diabetes Care*, 26.3:810-18, **2003**.
3. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF, and the DCCT/EDIC Research Group. "Autoimmune Response to Advanced Glycosylation End-Products of Human LDL." *Journal of Lipid Research*, 44.3:487-93, **2003**.
2. Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G. "Oxidized LDL-Anti-Oxidized LDL Immune Complexes and Diabetic Nephropathy." *Diabetologia*, 45:1562-71, **2002**.
1. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, and the DCCT/EDIC Research Group. "Proatherogenic and Proinflammatory Properties of Immune Complexes Prepared with Purified Human oxLDL Antibodies and Human oxLDL." *Clinical Immunology*, 105.1: 81-92, **2002**.

#### **LIPOPROTEIN DISTRIBUTION/OBESITY GROUP (Under EDIC)**

2. Purnell JQ, Dev RK, Steffes MW, Cleary PA, Palmer JP, Hirsch IB, Hokanson JE, and Brunzell JD. "Relationship of Family History of Type 2 Diabetes, Hypoglycemia and Autoantibodies to Weight Gain and Lipids with Intensive and Conventional Therapy in the Diabetes Control and Complications Trial." *Diabetes*, 52:2623-2629, **2003**.
1. Purnell JQ, Tsai A, Hokanson J, Cleary PA, Steffes M, Jacobs D, Brunzell J. "Weight Gain with Intensive Therapy but not Conventional Therapy of Type 1 Diabetes in DCCT is Greater than a Non-diabetic Population (Cardia): Follow-up from 1985 – 1993." *Diabetes*, 50(Supp2) A208, **2001**.

### **Genetics Studies (Under EDIC)**

1. Boright A, Paterson A, Mirea S, Bull S, Scherer B, Zinman B, and the DCCT/EDIC Research Group. "Genetic Variation at the ACE Gene is associated with persistent Microalbuminuria and severe Nephropathy in Type 1 Diabetes. The DCCT/EDIC Genetics Study." *Diabetes*, 54:1238-1244, **2005**.

### **FIRST AWARD**

1. Li Z and Gastwirth JL. A weighted test using both extreme discordant and concordant sib pairs for detecting linkage. *Genetic Epidemiology*, 20:34-43, **2001**.

### **GENETICS OF KIDNEYS IN DIABETES (GOKIND)**

1. Mueller PW, Rogus JJ, Cleary PA, Zhao Y, Smiles AM, Steffes MW, Bucksa J, Gibson TB, Corodvado SK, Krolewski AS, Nierras CR, Warram JH for the GoKindD Research Group. "Genetics of Kidneys in Diabetes (GoKinD) Study: A Genetics Collection Available for Identifying Genetic Susceptibility Factors for Diabetic Nephropathy in Type 1 Diabetes." *American Society of Nephrology*, 17:1782-1790, **2006**.

### **GIRLS HEALTH ENRICHMENT MULTI-SITE STUDIES (GEMS)**

10. Kumanyika SK, Obarzanek E, Robinson TN and Beech B. "Supplement 1: Phase 1 of the Girls Health Enrichment Multi-Site Studies (GEMS)." *Ethnicity and Disease*, 13: S1-i – ii, **2003**.
9. Obarzanek E and Pratt CA. "Girls Health Enrichment Multi-Site Studies (GEMS): New Approaches to Obesity Prevention Among Young African-American Girls." *Ethnicity and Disease*, 13: S1-1 – 5, **2003**.
8. Rochon J, Klesges RC, Story M, Robinson TN, Baranowski T, Obarzanek E and Mitchell M. "Common Design Elements of the Girls Health Enrichment Multi-Site Studies (GEMS)." *Ethnicity and Disease*, 13: S1-6 – 14, **2003**.

7. Kumanyika SK, Story M, Beech BM, Sherwood NE, Baranowski JC, Powell TM, Cullen KW and Owens AS. "Collaborative Planning for Formative Assessment and Cultural Appropriateness in the Girls Health Enrichment Multi-Site Studies (GEMS): A Retrospective." *Ethnicity and Disease*, 13: S1-15 – 29, **2003**.
6. Baranowski T, Baranowski JC, Cullen DW, Thompson DI, Nicklas T, Zakeri IF and Rochon J. "The Fun, Food and Fitness Project (FFFP): The Baylor GEMS Pilot Study." *Ethnicity and Disease*, 13: S1-30 – 39, **2003**.
5. Beech BM, Klesges RC, Kumanyika SK, Murray DM, Klesges L, McClanahan B, Slawson D, Nunnally C, Rochon J, McLain-Allen B and Pree-Cary J. "Child- and Parent-Targeted Interventions: The Memphis GEMS Pilot Study." *Ethnicity and Disease*, 13: S1-40 – 53, **2003**.
4. Story M, Sherwood NE, Himes JH, Davis M, Jacobs Jr. DR, Cartwright Y, Smyth M and Rochon J. "An After-School Obesity Prevention Program for African-American Girls: The Minnesota GEMS Pilot Project." *Ethnicity and Disease*, 13: S1-54 – 64, **2003**.
3. Robinson TN, Killen JD, Kraemer HC, Wilson DM, Matheson DM, Haskell WL, Pruitt LA, Powell TM, Owens AS, Thompson NS, Flint-Moore NM, Davis GJ, Emig KA, Brown RT, Rochon J, Green S and Varady A. "Dance and Reducing Television Viewing to Prevent Weight Gain in African-American Girls: The Stanford GEMS Pilot Study." *Ethnicity and Disease*, 13: S1-65 – 77, **2003**.
2. Story M, Sherwood NE, Obarzanek E, Beech BM, Baranowski JC, Thompson NS, Owens AS, Mitchell M and Rochon J. "Recruitment of African-American Pre-Adolescent Girls into an Obesity Prevention Trial: The GEMS Pilot Studies." *Ethnicity and Disease*, 13: S1-78 – 87, **2003**.
1. Kumanyika SK, Obarzanek E, Robinson TN, and Beech B. "Phase 1 of the Girls Health Enrichment Multi-Site Studies (GEMS): Conclusion." *Ethnicity and Disease*, 13: S1-88 – 91, **2003**.

## **LUPUS NEPHRITIS COLLABORATIVE STUDY GROUP**

9. Schwartz, MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ, and the Lupus Nephritis Collaborative Study Group. Irreproducibility of the activity and chronicity indices limits: Their utility in the management of lupus nephritis. *American Journal of Kidney Diseases*, 21:374-377, **1993**.
8. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ and the Lupus Nephritis Collaborative Study Group. Role of pathology indices in the management of severe lupus glomerulonephritis. *Kidney International*, 42:743-748, **1992**.

7. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, and Lachin JM for the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. *The New England Journal of Medicine*, 326:1373-1379, **1992**.
6. Lachin JM, Lan SP and the Lupus Nephritis Collaborative Study Group. Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. *Controlled Clinical Trials*, 13:62-79, **1992**.
5. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, Lewis EJ and The Lupus Nephritis Collaborative Study Group. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: Results of treatment with prednisone and short-term oral cyclophosphamide. *Annals of Internal Medicine*, 116:114-123, **1992**.
4. Pohl MA, Lan, S, Berl T and the Lupus Nephritis Collaborative Study Group. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. *Annals of Internal Medicine*, 114:924-929, **1991**.
3. Clough JD, Lewis EJ, Lachin JM, and the Lupus Nephritis Collaborative Study Group, et al. *Treatment protocols of the Lupus Nephritis Collaborative Study of plasmapheresis in severe lupus nephritis*. Apheresis, Alan R. Liss, Inc., 301-307, **1990**.
2. Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, and the Lupus Nephritis Collaborative Study Group. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. *Kidney International*, 36:891-896, **1989**.
  
1. Schwartz MM, Lan SP, Bonsib SM, Gephardt GN, Sharma HM and the Lupus Nephritis Collaborative Study Group. "Clinical Outcome of Three Discrete Histologic Patterns of Injury in Severe Lupus Glomerulonephritis." *American Journal of Kidney Diseases*, 13:273-283, **1989**.

## **MATERNAL FETAL MEDICINE UNITS (MFMU)**

172. Sibai B, Romero R, Klebanoff MA, Murguia Rice M, Caritis S, Lindheimer MD, Van Dorsten JP, Landon M, Miodovnik M, Dombrowski M, Meis P, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are

- increased prior to the diagnosis of preeclampsia. *Obstetrics and Gynecology*, 200:630.e1-630.e8, **2009**
171. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner MW, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of preterm birth in triplets using 17 alpha hydroxyprogesterone caproate: a randomized controlled trial. *Obstetrics and Gynecology*, 113:285-292, **2009**.
  170. Grobman WA, Lai Y, Landon MB, Spong C, Leveno K, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, O'Sullivan MJ, Sibai BM, Langer O, Thorp J, Ramin SM, Mercer BM; for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can a prediction model for vaginal birth after cesarean also predict the probability of morbidity related to a trial of labor? *American Journal of Obstetrics and Gynecology*, 200:56.e1-56.e6, **2009**.
  169. Tita ATN, Landon MB, Spong CY, Lai Y, Leveno KJ, Varner MW, Moawad AH, Caritis SN, Meis PJ, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the *Eunice Kennedy Shriver* NICHD Maternal-Fetal Medicine Units Network. Timing of elective repeat cesarean delivery at term and neonatal outcomes. *New England Journal of Medicine*, 360:111-120, **2009**.
  168. Ehrenberg HM, Iams JD, Goldenberg RL, Newman RB, Weiner SJ, Sibai BM, Caritis SN, Miodovnik M, Dombrowski MP, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal obesity, uterine activity, and the risk of spontaneous preterm birth. *Obstetrics and Gynecology*, 113:48-52, **2009**.
  167. Klebanoff MA, Meis PJ, Dombrowski MP, Zhao Y, Moawad AH, Northen A, Sibai BM, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Leveno KJ, Miodovnik M, Conway D, Wapner RJ, Carpenter M, Mercer BM, Ramin SM, Thorp JM, Peaceman AM; for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Salivary progesterone and estriol among pregnant women treated with 17-a-hydroxyprogesterone caproate or placebo. *American Journal of Obstetrics and Gynecology*, 199:506.e1-506.e7, **2008**.
  166. Alexander JM, Leveno KJ, Rouse D, Landon MB, Gilbert SA, Spong CY, Varner MW, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development

- Maternal-Fetal Medicine Units Network. Cesarean delivery for the second twin. *Obstetrics and Gynecology*, 112:748-752, **2008**.
165. Newman RB, Goldenberg RL, Iams JD, Meis PJ, Mercer BM, Moawad AH, Thom E, Miodovnik M, Caritis SN, Dombrowski M, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Preterm prediction study comparison of the cervical score and bishop score for prediction of spontaneous preterm delivery. *Obstetrics and Gynecology*, 112:508-515, **2008**.
164. Grobman WA, Lai Y, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM; for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. *American Journal of Obstetrics and Gynecology*, 199:30.e1-30.e5, **2008**.
163. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM, for the *Eunice Kennedy Shriver* NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. *New England Journal of Medicine*, 359:895-905, **2008**.
162. Mastrobattista JM, Klebanoff MA, Carey JC, Hauth JC, Thom EA, Ernest JM, Cotroneo M, Wapner RJ, Varner MW, Iams JD, Moawad AH, Sibai BM, Miodovnik M, Dombrowski MP, O'Sullivan MJ, VanDorsten JP, Langer O, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy. *American Journal of Perinatology*, 25:233-237, **2008**.
161. Carroll MA, Vidaeff AC, Mele L, Wapner RJ, Mercer BM, Peaceman AM, Sorokin Y, Dudley DJ, Spong CY, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Thorp JM, Moawad AH, O'Sullivan MJ, Carpenter MW, Rouse DJ, Sibai BM, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Bone Metabolism in Pregnant Women Exposed to Single

- Compared With Multiple Courses of Corticosteroids. *Obstetrics and Gynecology*, 111:1352-1358, **2008**.
160. Sciscione A, Landon MB, Leveno KJ, Spong CY, MacPherson CA, Varner MW, Rouse DJ, Moawad AH, Caritis SN, Harper M, Sorokin Y, Miodovnik M, Marshall, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, and Mercer BM, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Previous preterm cesarean delivery and risk of subsequent uterine rupture. *Obstetrics and Gynecology*, 111:648-653, **2008**.
  159. Mercer BM, Gilbert S, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Simhan HN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Labor outcomes with increasing number of prior vaginal births after cesarean delivery. *Obstetrics and Gynecology*, 111:285-291, **2008**.
  158. Bailit JL, Landon MB, Lai Y, Rouse DJ, Spong CY, Varner MW, Moawad AH, Simhan HN, Harper, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O; for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. MFMU Cesarean Registry: impact of shift change on cesarean complications. *American Journal of Obstetrics and Gynecology*, 198:173.e1-173.e5, **2008**.
  157. Spong CY, Landon MB, Gilbert S, Rouse DJ, Leveno KJ, Varner MW, Moawad AH, Simhan HN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstetrics and Gynecology*, 110:801-807, **2007**.
  156. Grobman WA, Gersnoviez R, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Pregnancy outcomes for women with placenta previa in relation to the number of prior cesareans. *Obstetrics and Gynecology*, 110:1249-1255, **2007**.

155. Varner MW, Thom EA, Spong CY, Landon MB, Leveno KJ, Rouse DJ, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin RJ, Miodovnik M, Carpenter MW, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Trial of labor after one previous cesarean delivery for multifetal gestation. *Obstetrics and Gynecology*, 110:814-819, **2007**.
154. Northen AT, Norman GS, Anderson K, Moseley L, DiVito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast J, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson G, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Follow-up of children exposed in-utero to 17-alpha hydroxyprogesterone caproate versus placebo. *Obstetrics and Gynecology*, 110:865-872, **2007**.
153. Landon MB, Thom EA, Spong CY, Carpenter MW, Mele L, Johnson F, Tillinghast J, Anderson G for the NICHD Maternal-Fetal Medicine Units Network. The NICHD MFMU-Network randomized clinical trial in progress: standard therapy versus no therapy for mild gestational diabetes mellitus. *Diabetes Care*, 30:S194-S199, **2007**.
152. Louis J, Landon MB, Gersnoviez RJ, Leveno KJ, Spong CY, Hauth JC, Moawad AH, Varner MW, Caritis SN, Harper M, Wapner RJ, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The MFMU Cesarean Registry: perioperative morbidity among HIV infected women undergoing cesarean delivery. *Obstetrics and Gynecology*, 110:385-390, **2007**.
151. Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Malone F, Caritis SN, Mercer BM, Harper M, Rouse DJ, Thorp JM, Ramin SM, Carpenter MW, Gabbe SG, for the National Institute of Child Health and Development Maternal-Fetal Medicine Units Network. Long term outcomes of a randomized trial of repeat antenatal corticosteroids. *New England Journal of Medicine*, 357:1190-1198, **2007**.
150. Sawady J, Mercer BM, Wapner RJ, Zhao Y, Sorokin Y, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Thorp JM, Ramin SM, Carpenter MW, Rouse DJ for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Beneficial effects of antenatal repeated steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. *American Journal of Obstetrics and Gynecology*, 197:281.e1-281.e8, **2007**.

149. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner MW, Malone F, Iams JD, Mercer BM, Thorp JM, Sorokin Y, Carpenter MW, Lo J, Ramin SM, Harper M, Anderson G, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. *New England Journal of Medicine*, 357:454-461, **2007**.
148. Hendler I, Andrews WW, Carey CJ, Klebanoff MA, Noble WD, Sibai BM, Hillier SL, Dudley D, Ernest JM, Leveno KJ, Wapner RJ, Iams JD, Varner MW, Moawad AH, Miodovnik M, O'Sullivan MJ, Van Dorsten PJ; for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The relationship between resolution of asymptomatic bacterial vaginosis and spontaneous preterm birth in fetal fibronectin-positive women. *American Journal of Obstetrics and Gynecology*, 197:488.e1-488.e5, **2007**.
147. Grobman WA, Lai Y, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Development of a nomogram for prediction of vaginal birth after cesarean delivery. *Obstetrics and Gynecology*, 109:806-812, **2007**.
146. Berghella V, Owen J, MacPherson CA, Yost NP, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Natural history of cervical funneling in women at high risk for spontaneous preterm birth. *Obstetrics and Gynecology*, 109:863-869, **2007**.
145. Alexander JM, Leveno KJ, Rouse DJ, Landon MB, Gilbert S, Spong CY, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor. *Obstetrics and Gynecology*, 109:917-921, **2007**.
144. Grobman WA, Gilbert S, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter MW, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Outcomes of induction of labor after one prior cesarean. *Obstetrics and Gynecology*, 109:262-269, **2007**.

143. Grobman WA, Lai Y, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM for the National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). "Development of a Nomogram for Prediction of Vaginal Birth After Cesarean Delivery." *Obstetrics and Gynecology*, 109: 806-812, **2007**.
142. Newman RB, Iams JD, Das A, Goldenberg RL, Meis P, Moawad A, Sibai BM, Caritis SN, Miodovnik M, Paul RH, Dombrowski MP, Fischer M; for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "A prospective masked observational study of uterine contraction frequency in twins." *American Journal of Obstetrics and Gynecology*, 195:1564-157, **2006**.
141. Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley D, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Mercer BM, Thorp JM, Moawad A, O'Sullivan MJ, Ramin S, Carpenter MW, Rouse DJ, Sibai B, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "Single vs. weekly courses of antenatal corticosteroids: Evaluation of safety and efficacy." *American Journal of Obstetrics & Gynecology*, 195:633-642, **2006**.
140. Alexander JM, Leveno KJ, Hauth JC, Landon MB, Thom E, Leindecker S, Spong CY, Varner MW, Moawad AH, Johnson F, McCampbell J, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Fetal injury associated with cesarean delivery." *Obstetrics and Gynecology*, 108: 885-890, **2006**.
139. Bloom SL, Spong CY, Thom E, Varner MW, Rouse DJ, Weininger S, Ramin SM, Caritis SN, Peaceman A, Sorokin Y, Sciscione A, Carpenter M, Mercer B, Thorp J, Malone F, Harper M, Iams J, Anderson G for the NICHD Maternal-Fetal Medicine Units Network. "A randomized trial of fetal pulse oximetry." *New England Journal of Medicine*, 355:2195-202, **2006**.
138. Bailit JL, Landon MB, Thom E, Rouse DJ, Spong CY, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner, RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: impact of time of day on cesarean complications." *American Journal of Obstetrics and Gynecology*, 195:1132-7, **2006**
137. Durnwald CP, Hauth JC, Leveno KJ, Spong CY, MacPherson C, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM, Gabbe SG for the NICHD Maternal-

- Fetal Medicine Units Network. "The MFMU Cesarean Registry: Safety and efficacy of a trial of labor in preterm pregnancy after a prior cesarean delivery." *American Journal of Obstetrics and Gynecology*, 195:1119-1126, **2006**.
136. Peaceman AM, Gersnoviez R, Landon MB, Spong CY, Leveno KJ, Varner MW, Rouse DJ, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Impact of fetal size on trial of labor success for patients with prior cesarean for dystocia." *American Journal of Obstetrics and Gynecology*, 195:1127-1131, **2006**.
  135. Aagaard-Tillery K, Sibai B, Spong CY, Momirova V, Wendel G, Wenstrom K, Samuels P, Moawad A, Caritis SN, Sorokin Y, Meis P, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "Sample bias among women with retained DNA samples for future genetic studies." *Obstetrics and Gynecology*, 108:1115-1120, **2006**.
  134. Rouse DJ, MacPherson C, Landon M, Varner MW, Leveno KJ, Moawad AH, Spong CY, Caritis SN, Meis PJ, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Blood Transfusion and Cesarean Delivery." *Obstetrics and Gynecology*, 108:891-897, **2006**.
  133. Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, Newman RB, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Paul RH, Varner MW, O'Sullivan M, Thurnau GR, Conway DL for the NICHD Maternal-Fetal Medicine Units Network. "Spirometry Is Related to Perinatal Outcomes in Pregnant Asthmatic Women." *American Journal of Obstetrics & Gynecology*, 194:120-126, **2006**.
  132. Landon MB, Spong CY, Thom E, Hauth JC, Bloom SL, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Risk of Uterine Rupture with a Trial of Labor in Women with Multiple and Single Prior Cesarean Delivery." *Obstetrics and Gynecology*, 108:12-20, **2006**.
  131. Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M,

- Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM for the NICHD Maternal-Fetal Medicine Units Network. "Maternal Morbidity Associated with Multiple Repeat Cesarean Deliveries." *Obstetrics and Gynecology*, 107:1226-1232, **2006**.
130. Hibbard JU, Gilbert S, Landon MB, Hauth JC, Leveno KJ, Spong CY, Varner MW, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "Trial of Labor or Repeat Cesarean Delivery in Women with Morbid Obesity and Previous Cesarean Delivery." *Obstetrics and Gynecology*, 108:124-133, **2006**.
129. Hendler I, Schatz M, Momirova V, Wise R, Landon M, Mabie W, Newman RB, Kiley J, Hauth JC, Moawad A, Caritis SN, Spong CY, Leveno KJ, Miodovnik M, Meis P, Wapner RJ, Paul RH, Varner MW, O'Sullivan MJ, Thurnau GR, Conway DL for the NICHD Maternal-Fetal Medicine Units Network. "Association of Obesity with Pulmonary and Non-Pulmonary Complications of Pregnancy in Asthmatic Women." *Obstetrics and Gynecology*, 108:77-82, **2006**.
128. Bloom SL, Leveno KJ, Spong CY, Gilbert S, Hauth JC, Landon MB, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Decision-to-Incision Times and Maternal and Infant Outcomes." *Obstetrics and Gynecology*, 108:6-11, **2006**.
127. Mercer BM, Rabello YA, Thurnau GR, Miodovnik M, Goldenberg RL, Das AF, Meis PJ, Moawad AH, Iams JD, Van Dorsten JP, Dombrowski MP, Roberts JM, McNellis D for the NICHD Maternal-Fetal Medicine Units Network. "The NICHD MFMU Antibiotic Treatment of pPROM Study: Impact of Initial Amniotic Fluid Volume on Pregnancy Outcome." *American Journal of Obstetrics and Gynecology*, 194:438-445, **2006**.
126. Yost NP, Owen J, Berghella V, Thom E, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai B for the NICHD Maternal-Fetal Medicine Units Network. "The Effect of Coitus on Recurrent Preterm Birth." *Obstetrics and Gynecology*, 107:793-97, **2006**.
125. Mercer BM, MacPherson C, Goldenberg, RL, Goepfert AR, Haugel-de Mouzon S, Varner MW, Iams JD, Meis PJ, Moawad AH, Miodovnik M, Caritis SN, Van Dorsten JP, Sorokin, Y, Thurnau GR, Spong CY for the NICHD Maternal-Fetal Medicine Units Network. "Are Women with Recurrent Spontaneous Preterm Births Different from Those Without Such History?" *American Journal of Obstetrics and Gynecology*, 194:1176-85, **2006**.

124. Andrews WW, Klebanoff MA, Thom EA, Hauth JC, Carey JC, Meis PJ, Caritis SN, Leveno KJ, Wapner RJ, Varner MW, Iams JD, Moawad A, Miodovnik M, Sibai B, Dombrowski M, Langer O, O'Sullivan MJ, for the NICHD Maternal-Fetal Medicine Units Network. "Mid-Pregnancy Genitourinary Tract Infection with Chlamydia Trachomatis: Association with Subsequent Preterm Delivery in Women with Bacterial Vaginosis and Trichomonas Vaginalis." *American Journal of Obstetrics and Gynecology*, 194:493-500, **2006**.
123. Goepfert AR, Varner M, Ward K, MacPherson C, Klebanoff M, Mercer B, Meis P, Iams J, Moawad A, Carey JC, Leveno K, Wapner R, Caritis SN, Miodovnik M, Sorokin Y, O'Sullivan MJ, Van Dorstein JP, Langer O for the NICHD Maternal-Fetal Units Network. "Differences in inflammatory cytokine and toll-like receptor genes and bacterial vaginosis in pregnancy." *American Journal of Obstetrics and Gynecology*, 193:1478-1485, **2005**.
122. Rouse DJ, Leindecker S, Landon M, Bloom SL, Varner MW, Moawad AH, Spong CY, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Predictability of uterine atony after primary cesarean delivery." *American Journal of Obstetrics and Gynecology*, 193:1127-1131, **2005**.
121. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S for the NICHD Maternal-Fetal Medicine Units Network. "Progesterone for Prevention of Recurrent Preterm Birth: Impact of gestational age at previous delivery." *American Journal of Obstetrics and Gynecology*, 193:1056-1060, **2005**.
120. Sibai B, Meis PJ, Klebanoff M, Dombrowski MP, Weiner SJ, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S for the NICHD Maternal-Fetal Medicine Units Network. "Plasma CRH measurement at 16-20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery." *American Journal of Obstetrics and Gynecology*, 193:1181-1186, **2005**.
119. Landon MB, Leindecker S, Spong CY, Hauth JC, Bloom S, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner, RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM, Gabbe SG for the NICHD Maternal-Fetal

- Medicine Units Network. "The MFMU Cesarean Registry: Factors affecting the success of trial of labor following prior cesarean delivery." *American Journal of Obstetrics and Gynecology*, 193:1016-1023, **2005**.
118. Thom EA, Klebanoff MA. "Issues in clinical trial design: Stopping a trial early & the large and simple trial." *American Journal of Obstetrics and Gynecology*, 193.3: 619-625, **2005**.
117. Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Does progesterone treatment influence risk factors for recurrent preterm delivery?" *Obstetrics and Gynecology*, 106.3: 557-561, **2005**.
116. Sheffield JS, Andrews WW, Klebanoff MA, MacPherson C, Carey J, Ernest JM, Wapner RJ, Trout W, Moawad A, Miodovnik M, Sibai B, Varner MW, Caritis SN, Dombrowski M, Langer O, O'Sullivan MJ, for the NICHD Maternal-Fetal Medicine Units Network. "Spontaneous resolution of asymptomatic chlamydia trachomatis in pregnancy." *Obstetrics and Gynecology*, 105.3: 557 – 562, **2005**.
115. Varner MW, Leindecker S, Hibbard JU, Hauth JC, Landon M, Leveno K, Sorokin Y, Harper M, Caritis SN, Wapner R, Miodovnik M, Sibai B, Carpenter M, Conway D, Mercer B, Thorp, J, Peaceman A, O'Sullivan MJ, Ramin S, Malone F, Gabbe S for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Trial of labor with a twin gestation." *American Journal of Obstetrics and Gynecology*, 193.1: 135-40, **2005**.
114. Hendler I, Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, MacPherson CA, Caritis SN, Miodovnik M, Menard MK, Thurnau GR, Sorokin Y, for the NICHD Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Association between maternal body mass index (BMI) and spontaneous and indicated preterm birth." *American Journal of Obstetrics and Gynecology*, 192.3: 882-886, **2005**.
113. Bloom SL, Spong CY, Weiner SJ, Landon MB, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai B, Langer O, Gabbe SG, for the NICHD Maternal-Fetal Medicine Units Network. "Complications of Anesthesia for Cesarean Delivery." *Obstetrics and Gynecology*, 106.2: 281-287, **2005**.

112. Hnat MD, Mercer BM, Miodovnik M, Thurnau G, Goldenberg R, Thom E, Meis P, Moawad A, Iams JD, Van Dorsten JP, Paul RH for the NICHD Maternal-Fetal Medicine Units Network. "Perinatal outcomes in women with preterm rupture of membranes between 24-32 weeks of gestation and a history of vaginal bleeding." *American Journal of Obstetrics & Gynecology*, 193.1: 164-168, **2005**.
111. Varner VW, Noble, WD, Dombrowski M, Sibai B, Rouse DJ, Paul R, Caritis SN, Miodovnik M, Moawad A, Iams, JD, Witter F, Romero R, Leveno K, Meis P, Wapner R, Rosen M, Thurnau G, Van Dorsten P, O'Sullivan MJ, Conway D for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Is there a seasonal variation in the diagnosis of oligohydramnios?" *The Journal of Maternal-Fetal and Neonatal Medicine*, 17.3: 173-177, **2005**.
110. Klebanoff MA, Hillier SL, Nugent RP, MacPherson CA, Hauth JC, Carey JC, Ernest JM, Wapner RJ, Trout W, Moawad A, Leveno KJ, Miodovnik M and the NICHD Maternal-Fetal Medicine Units Network. "Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation?" *American Journal of Obstetrics & Gynecology*, 192.2: 470-477, **2005**.
109. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G, Wenstrom K, Samuels P, Cotroneo M, Moawad A, Sorokin Y, Meis P, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ, Gabbe SG, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, Maryland. "The relationship of the Factor V Leiden mutation and pregnancy outcomes for mother and fetus." *Obstetrics and Gynecology*, 106.3: 517-524, **2005**.
108. Landon MB, Hauth JC, Leveno JK, Spong CY, Leindecker MS, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Conway D, Thorp JM, Ramin SM, Mercer BM, Gabbe SG, for the NICHD Maternal-Fetal Medicine Units Network. "The MFMU Cesarean Registry: Maternal and Perinatal Outcomes Associated with a Trial of Labor After Prior Cesarean Delivery." *New England Journal of Medicine*, 351.25: 2581-2589, **2004**.
107. Rouse DJ, Landon M, Leveno KJ, Leindecker S, Varner MW, Caritis SN, O'Sullivan MJ, Wapner RJ, Meis PJ, Miodovnik M, Sorokin Y, Moawad AH, Mabie W, Conway D, Gabbe S, Spong CY for the NICHD Maternal-Fetal Medicine Units Network. "The Maternal-Fetal Medicine Units Cesarean Registry: Chorioamnionitis at term and its duration –

- relationship to outcomes.” *American Journal of Obstetrics & Gynecology*, 191.1: 211-6, **2004**.
106. Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, Newman RB, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Paul RH, Varner MW, O’Sullivan M, Thurnau GR, Conway DL, for the NICHD Maternal-Fetal Medicine Units Network. “The relationship of asthma medication use to perinatal outcomes.” *Journal of Allergy and Clinical Immunology*, 113.6: 1040-1045, **2004**.
  105. Knudtson EJ, Smith K, Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Meis PJ, Moawad AH, VanDorsten JP, Paul RH, Sorokin Y, Roberts JM, Das A, for the NICHD Maternal-Fetal Medicine Units Network. “Serum homocysteine levels after preterm premature rupture of the membranes.” *American Journal of Obstetrics & Gynecology*, 191.2: 537-541, **2004**.
  104. Berghella V, Iams JD, Newman, RB, MacPherson C, Goldenberg RL, Mueller-Heubach E, Caritis SN, Dombrowski MP, for the NICHD Network of Maternal-Fetal Medicine Units Network. “Frequency of uterine contractions in asymptomatic pregnant women with or without a short cervix on transvaginal ultrasound scan.” *American Journal of Obstetrics & Gynecology*, 191.4: 1253-1256, **2004**.
  103. Owen J, Yost N, Berghella V, MacPherson, C, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai B for the Maternal-Fetal Medicine Units, Bethesda, MD. “Can shortened mid-trimester cervical length predict very early spontaneous preterm birth?” *American Journal of Obstetrics & Gynecology*, 191.1: 298-303, **2004**.
  102. Yost NP, Owen J, Berghella V, MacPherson C, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai B, for the NICHD Maternal-Fetal Medicine Units Network. “Number and gestational age of prior preterm births does not modify the predictive value of a short cervix.” *American Journal of Obstetrics & Gynecology*, 191.1: 241-6, **2004**.
  101. How H, Sibai B, Lindheimer M, Caritis S, Hauth J, Klebanoff M, MacPherson C, Van Dorsten P, Miodovnik M, Landon M, Paul R, Meis P, Thurnau G, Dombrowski M, Roberts J. “Is Early-Pregnancy Proteinuria Associated with an Increased Rate of Preeclampsia in Women with Pregestational Diabetes Mellitus?” *American Journal of Obstetrics & Gynecology*, 190.3: 775-78, **2004**.
  100. Yost NP, Owen J, Berghella V, MacPherson C, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai B, for the NICHD Maternal Fetal Medicine Units Network. “Second-Trimester Cervical Sonography: Features Other

- Than Cervical Length for the Prediction of Spontaneous Preterm Birth.” *Obstetrics & Gynecology*, 103.3: 457-462, **2004**.
99. Dombrowski M, Schatz M, Wise R, Thom E, Landon M, Mabie W, Newman R, McNellis D, Hauth J, Lindheimer M, Caritis S, Leveno K, Meis P, Miodovnik M, Wapner R, Varner M, O’Sullivan M, Conway D, for the NICHD Maternal-Fetal Medicine Units Network and The NHLBI. “Randomized Trial of Inhaled Beclomethasone Dipropionate versus Theophylline for Moderate Asthma During Pregnancy.” *American Journal of Obstetrics & Gynecology*, 190.3: 737-44, **2004**.
  98. Klebanoff M, Hauth JC, MacPherson C, Carey JC, Heine P, Wapner R, Iams J, Moawad A, Miodovnik M, Sibai B, VanDorsten JP, Dombrowski MP for the NICHD Maternal Fetal Medicine Units Network. “Time Course of the Regression of Asymptomatic Bacterial Vaginosis in Pregnancy with and without Treatment.” *American Journal of Obstetrics & Gynecology*, 190.2: 363-70, **2004**.
  97. Dombrowski MP, Schatz M, Wise R, Momirova, M, Landon M, Mabie W, Newman R, McNellis D, Hauth J, Lindheimer M, Caritis S, Leveno K, Meis P, Miodovnik M, Wapner R, Paul R, Varner M, O’Sullivan M, Thurnau G, Conway D for The NICHD Maternal-Fetal Medicine Units Network, and The NHLBI. “Asthma During Pregnancy.” *Obstetrics & Gynecology*, 103.1: 5-12, **2004**.
  96. Newman RB, Johnson F, Das A, Goldenberg RL, Swain M, Moawad A, Sibai BM, Caritis SN, Miodovnik M, Paul RH, Dombrowski MP, Collins-Sharp BA, Fischer M for the NICHD MFMU Network. “Uterine Contraction Frequency Before and After Successful Tocolytic Therapy for Preterm Uterine Contractions.” *Journal of Reproductive Medicine*, 48.11: 843-9, **2003**.
  95. Meis P, Klebanoff M, Thom E, Dombrowski M, Sibai S, Moawad A, Spong C, Hauth J, Miodovnik M, Varner M, Leveno K, Caritis S, Iams J, Wapner R, Conway D, O’Sullivan M, Carpenter M, Mercer B, Ramin S, Thorp J, Peaceman A, for the NICHD Maternal Fetal Medicine Units Network. “Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate.” *New England Journal of Medicine*, 348.24: 2379-85, **2003**.
  94. Thom E, Rouse D for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Conducting Randomized Controlled Trials in the NICHD MFMU Network.” *Seminars in Perinatology*, 27.3: 253-260, June **2003**.
  93. Iams, JD and Mercer BM for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Antenatal Prediction of

- Neonatal Morbidity and Mortality.” *Seminars in Perinatology*, 27.3: 247-252, June **2003**.
92. Sibai BM, Caritis S, Hauth J for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Preeclampsia.” *Seminars in Perinatology*, 27.3: 239-246, June **2003**.
  91. Andrews WW and Goldenberg RL for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned from an Antibiotic Trial in Fetal Fibronectin Positive Women.” *Seminars in Perinatology*, 27.3: 231-238, June **2003**.
  90. Mercer BM, Goldenberg RL, Das AF, Thurnau GR, Bendon RW, Miodovnik M, Ramsey RD, Rabello YA for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned Regarding Antibiotic Therapy for the Reduction of Infant Morbidity after Preterm Premature Rupture of the Membranes.” *Seminars in Perinatology*, 27.3: 217-203, June **2003**.
  89. Carey JC and Klebanoff MA. for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Vaginal Infections and Preterm Birth?” *Seminars in Perinatology*, 27.3: 212-216, June **2003**.
  88. Iams JD for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Uterine Contractions and Preterm Birth: The HUAM Prediction Study.” *Seminars in Perinatology*, 27.3: 204-211, June **2003**.
  87. Iams JD and Owen J for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about Cervical Ultrasound.” *Seminars in Perinatology*, 27.3: 194-203, June **2003**.
  86. Goldenberg RL, Iams JD, Mercer BM, Meis, P, Moawad A, Das A, Copper R, Johnson F for the NICHD Maternal Fetal Medicine Units Network. “What We Have Learned about the Predictors of Preterm Birth.” *Seminars in Perinatology*, Vol 27.3: 185-193, June **2003**.
  85. Meis P, Spong C and Thom EA (eds). “Introduction.” *Seminars in Perinatology*, 27.3: 183-184, June **2003**.
  84. Andrews WW, Sibai BM, Thom EA, Dudley D, Ernest JM, McNellis D, Leveno KJ, Wapner R, Moawad A, O'Sullivan MJ, Caritis SN, Iams JD, Langer O, Miodovnik M, Dombrowski M and the NICHD Maternal Fetal Medicine Units Network: “A Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin-Positive Women.” *Obstetrics and Gynecology*, 101.5: 847-855, **2003**.
  83. Hauth J, Carey JC, Klebanoff M, Hillier S, MacPherson C, Ernest JM, Fischer ML, Heine P, Nugent R, Wapner RJ, Trout W, Moawad A, Leveno K, Miodovnik M, Sibai B, Van Dorsten JP, Dombrowski M, O'Sullivan M, Varner M, Langer O and the NICHD Maternal Fetal Medicine Units

- Network. "Early Pregnancy Threshold Vaginal pH and Gram Stain Scores Predictive of Subsequent Preterm Birth." *American Journal of Obstetrics and Gynecology*, 188.3: 831-5, **2003**.
82. Schatz M, Dombrowski M, Wise R, Thom EA, Landon M, Mabie W, Newman R, Hauth J, Lindheimer M, Caritis S, Leveno K, Meis P, Miodovnik M, Wapner R, Paul R, Verner M, O'Sullivan M, Thurnau G, Conway D, McNellis D for the NICHD Maternal Fetal Medicine Units Network. "Asthma Morbidity During Pregnancy Can Be Predicted by Asthma Severity Classification." *Journal of Allergy & Clinical Immunology*, 112.2: 283-8, **2003**.
81. Landon MB, Thom E, Spong CY, Gabbe SG, Leindecker S, Johnson F, Lain K, Miodovnik M, Carpenter M. "A Planned Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus." *Journal of Maternal-Fetal & Neonatal Medicine*, 11.4: 226-231, April **2002**.
80. Berghella V, Klebanoff M, McPherson C, Carey C, Hauth JC, Ernest JM, Heine RP, Wapner R, Trout W, Moawad A, Miodovnik M, Leveno K, Sibai B, Van Dorsten JP, Dombrowski MP, O'Sullivan MJ, Varner M, Langer O, for the NICHD Maternal Fetal Medicine Units Network. "Sexual Intercourse Association with Asymptomatic Bacterial Vaginosis and *Trichomonas Vaginalis* Treatment in Relationship to Preterm Birth." *American Journal of Obstetrics and Gynecology*, 187.5: 1277-1276, **2002**.
79. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M. "Perinatal Outcome in Women with Recurrent Preeclampsia Compared with Women Who Develop Preeclampsia as Nulliparas." *American Journal of Obstetrics and Gynecology*, 186.3: 422-6, **2002**.
78. Harger J, Ernest J, Thurnau G, Moawad A, Thom E, Landon M, Paul R, Miodovnik M, Dombrowski M, Sibai B, Van Dorsten P, McNellis D for the NICHD Maternal Fetal Medicine Units Network. "Frequency of Congenital Varicella Syndrome in a Prospective Cohort of 347 Pregnant Women." *Obstetrics and Gynecology*, 100.2: 260-5, **2002**.
77. Buchbinder A, Sibai BM, Caritis S, MacPherson C, Hauth J, Lindheimer MD, Klebanoff M, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, and Thurnau G, for the National Institute for Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia." *American Journal of Obstetrics and Gynecology*, 186.1: 66-71, **2002**.
76. Harger JH, Ernest JM, Thurnau GR, Moawad A, Momirova V, Landon MB, Paul R, Miodovnik M, Dombrowski M, Sibai B, and VanDorsten P, for the National Institute of Child Health and Human Development, Network of

- Maternal-Fetal Medicine Units. "Risk Factors and Outcome of Varicella-Zoster Virus Pneumonia in Pregnant Women." *The Journal of Infectious Diseases*, 185.4: 422-427, **2002**.
75. Wang EY, Woodruff TK, and Moawad A, for the National Institute for Child Health and Human Development Maternal-Fetal Medicine Units Network. "Follistatin-free activin A is not associated with preterm birth." *American Journal of Obstetrics and Gynecology*, 186.3: 464-469, **2002**.
  74. Moawad AH, Goldenberg RL, Mercer B, Meis PJ, Iams JD, Das A, Caritis SN, Miodovnik M, Menard MK, Thurnau GR, Dombrowski M, and Roberts JM, and the National Institute for Child Health and Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: The value of serum alkaline phosphatase, alpha-fetoprotein and plasma corticotropin-releasing hormone, and other serum markers for the prediction of spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 186.5: 990-996, **2002**.
  73. Ramsey PS, Tamura T, Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, Das A, VanDorsten JP, Caritis SN, Thurnau G, Dombrowski MP, and Miodovnik M, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Elevated cervical ferritin levels at 22-24 weeks gestation are associated with spontaneous preterm delivery in asymptomatic women." *American Journal of Obstetrics and Gynecology*, 186:458-463, **2002**.
  72. Iams JD, Newman RB, Thom EA, Goldenberg RL, Mueller-Heubach E, Moawad A, Sibai BM, Caritis SN, Miodovnik M, Paul RH, Dombrowski MP, and McNellis D for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Frequency of uterine contractions and the risk of spontaneous preterm delivery." *The New England Journal of Medicine*, 346.4: 250-255, **2002**.
  71. Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, Ernest JM, Heine RP, Wapner RJ, Trout W, Moawad A, Leveno KJ, and the National Institute for Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Failure of metronidazole to prevent preterm delivery among women with Asymptomatic Trichomonas Vaginalis infection." *New England Journal of Medicine*, 345.7:487-493, **2001**.
  70. Owen J, Yost N, Berghalla V, Thom E, Swain M, Dildy GA, Miodovnik M, Langer O, Sibai B, McNellis D, for the National Institute for Child Health and Human Development Maternal-Fetal Medicine Units Network. "Mid-trimester Endovaginal Sonography in Women at High Risk for Spontaneous Preterm Birth." *Journal of the American Medical Association*, 286:1340-1348, **2001**.

69. Goldenberg RL, Klebanoff M, Carey JC, and MacPherson C, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Metronidazole treatment of women with a positive fetal fibronectin test result." *American Journal of Obstetrics and Gynecology*, 185.2: 485-486, **2001**.
68. Goldenberg RL, Iams JD, Mercer BM, Meis PJ, Moawad A, Das A, Miodovnik M, VanDorsten PJ, Caritis SN, Thurnau G, and Dombrowski MP, for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "The Preterm Prediction Study: Toward a multiple-marker test for spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 185.3: 643-651, **2001**.
67. Branch DW, Porter TF, Rittenhouse L, Caritis S, Sibai B, Hogg B, Lindheimer MD, Klebanoff M, MacPherson C, VanDorsten JP, Landon M, Paul R, Miodovnik M, Meis P, and Thurnau G, for the National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. "Antiphospholipid antibodies in women at risk for preeclampsia." *American Journal of Obstetrics and Gynecology*, 184.5: 825-834, **2001**.
66. Iams JD, Goldenberg RL, Mercer BM, Moawad AH, Meis PJ, Das AF, Caritis SN, Miodovnik M, Menard MK, Thurnau GR, Dombrowski MP, and Roberts JH, for The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Can low risk women destined for spontaneous preterm birth be identified?" *American Journal of Obstetrics and Gynecology*, 184.4: 652-655, **2001**.
65. Goepfert AR, Goldenberg RL, Andrews WW, Hauth JC, Mercer B, Iams J, Meis P, Moawad A, Thom E, VanDorsten JP, Caritis ST, Thurnau G, Miodovnik M, Dombrowski M, Roberts J, and McNellis D, for The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Association between cervical interleukin 6 concentration and spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 184.3: 483-488, **2001**.
64. Newman RB, Goldenberg RL, Moawad AH, Iams JD, Meis PJ, Das A, Miodovnik M, Caritis SN, Thurnau GR, Dombrowski MP, and Roberts J, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Occupational fatigue and preterm premature rupture of membranes." *American Journal of Obstetrics and Gynecology*, 184.3: 438-446, **2001**.
63. Iams JD for The National Institute of Child Health and Human Development Maternal-Fetal Medicine Network Investigators, Goldsmith LT, and Weiss G. "The Preterm Prediction Study: Maternal Serum Relaxin, Sonographic Cervical Length, and Spontaneous Preterm Birth in Twins." *Journal of the Society for Gynecologic Investigation*, 8.1: 39-42, **2001**.

62. Sibai BM, Caritis SN, Hauth JC, MacPherson C, VanDorsten JP, Klebanoff M, Landon M, Paul RH, Meis PJ, Miodovnik M, Dombrowski MP, Thurnau GR, Moawad AH, and Roberts J, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies." *American Journal of Obstetrics and Gynecology*, 183.6: 1520-1524, **2000**.
61. Goepfert AR, Goldenberg RL, Mercer B, Iams J, Meis P, Moawad A, Thom E, VanDorsten JP, Caritis SN, Thurnau G, Miodovnik M, Dombrowski M, Roberts JM, and McNellis D, for the National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Quantitative fetal fibronectin values and the prediction of spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 183.6: 1480-1483, **2000**.
60. Alexander JM, Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Meis PJ, Moawad AH, Iams JD, VanDorsten JP, Paul RH, Dombrowski MP, Roberts JM and McNellis D. "The impact of digital cervical examination on expectantly managed preterm rupture of membranes." *American Journal of Obstetrics and Gynecology*, 183: 1003-1007, **2000**.
59. Andrews WW, Goldenberg RL, Mercer B, Iams J, Meis P, Moawad A, Das A, VanDorsten JP, Caritis SN, Thurnau G, Miodovnik M, Roberts J and McNellis D, for the National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 183.3: 662-668, **2000**.
58. Mercer BM, Goldenberg RL, Meis PJ, Moawad AH, Shellhaas C, Das A, Menard MK, Caritis SN, Thurnau GR, Dombrowski MP, Miodovnik M, Roberts JM and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Prediction of preterm premature rupture of membranes through clinical findings and ancillary testing." *American Journal of Obstetrics and Gynecology*, 183:738-745, **2000**.
57. Goldenberg RL, Klebanoff M, Carey JC, MacPherson C, Leveno KJ, Moawad AH, Sibai B, Heine RP, Ernest JM, Dombrowski MP, Miodovnik M, Wapner RJ, Iams JD, Langer O, O'Sullivan MJ and Roberts JM. "Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 183.2: 469-475, **2000**.

56. Sibai BM, Hauth J, Caritis S, Lindheimer MD, MacPherson CA, Klebanoff M, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M, Roberts J, and McNellis D, for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Hypertensive disorders in twin versus singleton gestations." *American Journal of Obstetrics and Gynecology*, 182.4: 938-942, **2000**.
55. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Dombrowski MP, Das A, Roberts JM and McNellis D. "Preterm prediction study: Is socioeconomic status a risk factor for bacterial vaginosis in black or in white women?" *American Journal of Perinatology*, 17: 41-45, **2000**.
54. Goldenberg RL, Andrews WW, Guerrant RL, Newman M, Mercer B, Iams J, Meis P, Moawad A, Das A, VanDorsten JP, Caritis SN, Thurnau G, Bottoms S, Miodovnik M, McNellis D and Roberts J, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth." *American Journal of Obstetrics and Gynecology*, 182.3:631-635, **2000**.
53. Goldenberg RL, Andrews WW, Mercer BM, Moawad AH, Meis PJ, Iams JD, Das A, Caritis SN, Roberts JM, Miodovnik M, Menard K, Thurnau G, Dombrowski MP and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The Preterm Prediction Study: Granulocyte Colony-Stimulating Factor and Spontaneous Preterm Birth." *American Journal of Obstetrics and Gynecology*, 182.3: 625-630, **2000**.
52. Goldenberg RL, Iams JD, Das A, Mercer BM, Meis PJ, Moawad AH, Miodovnik M, VanDorsten JP, Caritis SN, Thurnau GR, Dombrowski MP, Roberts JM and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Sequential cervical length and fetal fibronectin testing for the prediction of spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 182.3: 636-643, **2000**.
51. Sibai BM, Caritis S, Hauth J, Lindheimer M, VanDorsten JP, MacPherson C, Klebanoff M, Landon M, Miodovnik M, Paul R, Meis P, Dombrowski M, Thurnau G, Roberts J and McNellis D, for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus." *American Journal of Obstetrics and Gynecology*, 182.2: 364-370, **2000**.

50. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, Heine RP, Nugent RP, Fischer ML, Leveno KJ, Wapner R, Varner M, and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis." *The New England Journal of Medicine*, 342.8: 534-540, **2000**.
49. Goldenberg RL and Das A for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Fetal fibronectin and bacterial vaginosis in smokers and nonsmokers." *American Journal of Obstetrics and Gynecology*, 182.1:164-166, **2000**.
48. Dombrowski M, Thom E, McNellis D for the NICHD Maternal Fetal Medicine Units Network. "Maternal Fetal Medicine Units Network (MFMU) Studies of Inhaled Corticosteroids During Pregnancy." *Journal of Allergy and Clinical Immunology*. 103(2 Pt 2): S356-9, **1999**.
47. Mercer BM, MacPherson CA and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Reply to: Incidence of Morbidity. *American Journal of Obstetrics and Gynecology*, 181:1582, **1999**.
46. Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, Caritis SN, Miodovnik M, Menard MK, Thurnau GR, Dombrowski MP, Roberts JM and McNellis D for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Effect of gestational age and cause of preterm birth on subsequent obstetric outcome." *American Journal of Obstetrics and Gynecology*, 181.5: 1216-1221, **1999**.
45. Hogg B, Hauth JC, Caritis SN, Sibai BM, Lindheimer M, VanDorsten JP, Klebanoff M, MacPherson C, Landon M, Paul R, Miodovnik M, Meis PJ, Thurnau GR, Dombrowski MP, McNellis D and Roberts JM for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Safety of labor epidural anesthesia for women with severe hypertensive disease." *American Journal of Obstetrics and Gynecology*, 181.5: 1096-1101, **1999**.
44. Andrews WW, Tsao J, Goldenberg RL, Hauth JC, Mercer B, Iams J, Meis P, Moawad A, Das A, VanDorsten PJ, Caritis SN, Thurnau G, Miodovnik M, Roberts J and McNellis D. "The preterm prediction study: Failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth." *American Journal of Obstetrics and Gynecology*, 180.5: 1151-1154, **1999**.
43. Chapman SJ, Hauth JC, Bottoms SF, Iams JD, Sibai B, Thom E, Moawad AH, and Thurnau GR. "Benefits of maternal corticosteroid therapy in

- infants weighing  $\leq 1000$  grams at birth after preterm rupture of the amnion." *American Journal of Obstetrics and Gynecology*, 180.3:677-682, **1999**.
42. Bendon RW, Faye-Peterson O, Pavlova Z, Qureshi F, Mercer B, Miodovnik M, Das AF, Meis PJ, Moawad AH, Iams JD and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, MD, USA. "Fetal membrane histology in preterm premature rupture of the membranes: Comparison to controls, and between antibiotic and placebo treatment." *Pediatric and Developmental Pathology*, 2:552-558, **1999**.
  41. Bottoms SF, Paul RH, Mercer BM, MacPherson CA, Caritis SN, Moawad AH, VanDorsten JP, Hauth JC, Thurnau GR, Miodovnik M, Meis PM, Roberts JM, McNellis D and Iams JD. "Obstetric determinants of neonatal survival: Antenatal predictors of neonatal survival and morbidity in extremely low birth weight infants." *American Journal of Obstetrics and Gynecology*, 180.3:665-669, **1999**.
  40. Kimberlin DF, Hauth JC, Owen J, Bottoms SF, Iams JD, Mercer BM, Thom EA, Moawad AH, VanDorsten JP and Thurnau GR. "Indicated versus spontaneous preterm delivery: An evaluation of neonatal morbidity among infants weighing  $\leq 1000$  grams at birth." *American Journal of Obstetrics and Gynecology*, 180.3: 683-689, **1999**.
  39. Goepfert AR, Goldenberg RL, Hauth JC, Bottoms S, Iams JD, Mercer B, MacPherson CA, Moawad AH, VanDorsten, JP and Thurnau GR. "Obstetrical determinants of neonatal neurological morbidity in  $\leq 1000$  gram infants." *American Journal of Perinatology*, 16.1: 33-43, **1999**.
  38. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, MacPherson C, Landon M, Miodovnik M, Paul R, Meis P and Dombrowski M, for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. *The New England Journal of Medicine*, 339:667-671, **1998**.
  37. Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, MacPherson and Thurnau GR. "The effect of maternal magnesium sulfate treatment on neonatal morbidity in  $1000\leq$ -gram infants." *American Journal of Perinatology*, 15.11: 635-641, **1998**.
  36. Goldenberg RL, Mercer BM, Miodovnik M, Thurnau GR, Meis PJ, Moawad A, Paul RH, Bottoms SF, Das A, Roberts JM, McNellis D and Tamura T. "Plasma ferritin, preterm rupture of membranes, and pregnancy outcome." *American Journal of Obstetrics and Gynecology*, 179.6: 1599-1604, **1998**.
  35. Hauth J, Sibai B, Caritis S, VanDorsten P, Lindheimer M, Klebanoff M, MacPherson C, Landon M, Paul R, Miodovnik M, Meis P, Dombrowski M,

- Thurnau G, Walsh S, McNellis D, Roberts JM, and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Maternal serum thromboxane B<sub>2</sub> concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial." *American Journal of Obstetrics and Gynecology*, 179.5: 1193-1199, **1998**.
34. Caritis S, Sibai B, Hauth J, Lindheimer M, VanDorsten, Klebanoff M, Thom EA, Landon M, Paul P, Miodovnik M, Meis P, Thurnau G, Dombrowski M, McNellis D, Roberts J, and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Predictors of preeclampsia in women at high risk." *American Journal of Obstetrics and Gynecology*, 179.4: 946-951, **1998**.
  33. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, Das A, Roberts JM, and McNellis D, for the Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. "The preterm prediction study: Risk factors for indicated preterm births." *American Journal of Obstetrics and Gynecology*, 178:562-567, **1998**.
  32. Thom E and Das A. Letter to the Editor. Statisticians' Advice to Obstetricians. *American Journal of Obstetrics and Gynecology*, 178:192-193, **1998**.
  31. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G, and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Low-dose aspirin to prevent preeclampsia in women at high risk." *The New England Journal of Medicine*, 338.11: 701-705, **1998**.
  30. Goldenberg RL, Iams JD, Mercer BM, Meis PJ, Moawad AH, Copper RL, Das A, Thom E, Johnson F, McNellis D, Miodovnik M, VanDorsten JP, Caritis SN, Thurnau GR, Bottoms SF, and the NICHD MFMU Network. "The Preterm Prediction Study: The Value of New vs Standard Risk Factors in Predicting Early and All Spontaneous Preterm Births." *American Journal of Public Health*, 88.2: 233-238, **1998**.
  29. Mercer BM, Thom EA and Goldenberg RL. Reply to: Antibiotic Therapy for Premature Rupture of Membranes to Prevent Respiratory Distress Syndrome. *Journal of the American Medical Association*, 279:749, **1998**.
  28. Mercer BM and Das A. Reply to: Premature Rupture of Membranes, Antibiotics, and Amnioitis. *Journal of the American Medical Association*, 279:22, **1998**.
  27. Iams JD, Goldenberg RL, Mercer BM, Moawad AM, Thom E, Meis PJ, McNellis D, Caritas S, Miodovnik M, Menard MK, Thurnau GR, Bottoms SF and Roberts JM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The Preterm

- Prediction Study: Recurrence risk of spontaneous preterm birth.  
*American Journal of Obstetrics and Gynecology*, 178.5: 1035-1040, **1998**.
26. Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Meis PJ, Das A, McNellis D, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery." *American Journal of Obstetrics and Gynecology*, 177.1: 8-12, **1997**.
  25. Brost BC, Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, Newman RB, Miodovnik M, Caritis SN, Thurnau G, Bottoms SF, Das A and McNellis D. "The preterm prediction study: Association of cesarean delivery with increases in maternal weight and body mass index." *American Journal of Obstetrics and Gynecology*, 177.2: 333-337, **1997**.
  24. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, Rabello YA, Meis PJ, Moawad AH, Iams JD, VanDorsten JP, Paul RH, Bottoms SF, Merenstein G, Thom EA, Roberts JM and McNellis D, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: A randomized controlled trial." *Journal of the American Medical Association*, 278.12: 989-995, **1997**.
  23. Bendon RW, Faye-Peterson O, Pavlova Z, Qureshi F, Elder N, Das A, Hauth J, McNellis D, Mercer B, Miodovnik M, and the NICHD Maternal-Fetal Medicine Units Network. "Histologic features of chorio-amnion membrane rupture: Development of methodology." *Pediatric Pathology and Laboratory Medicine*, 17:27-42, **1997**.
  22. Bottoms SF, Paul RH, Iams JD, Mercer BM, Thom EA, Roberts JM, Caritis SN, Moawad AH, VanDorsten JP, Hauth JC, Thurnau GR, Miodovnik M, Meis PM and the National Institute for Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Obstetrical determinants of neonatal survival: Influence of willingness to perform cesarean delivery on survival of extremely low-birth-weight infants." *American Journal of Obstetrics and Gynecology*, 176.5: 960-966, **1997**.
  21. Copper RL, Goldenberg RL, Das A, Elder N, Swain M, Norman G, Ramsey R, Cotroneo P, Collins BA, Johnson F, Jones P, Meier A, and the National Institute of Child Health and Human Development Maternal-Fetal

- Medicine Units Network. "The Preterm Prediction Study: Maternal stress is associated with spontaneous preterm birth at less than thirty-five weeks' gestation." *American Journal of Obstetrics and Gynecology*, 175.5:1286-1292, **1996**.
20. Goldenberg RL, Iams JD, Miodovnik M, VanDorsten JP, Thurnau G, Bottoms S, Mercer BM, Meis PJ, Moawad AH, Das A, Caritis SN, McNellis D, and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: Risk factors in twin gestations." *American Journal of Obstetrics and Gynecology*, 175:1047-1053, **1996**.
  19. Gardner MO, Rouse DJ, Goldenberg RL, Lanning J, Thom E, Zachary J, and the NICHD Maternal-Fetal Medicine Unit Network. "Cost comparison of induction of labor versus expectant management in pregnancies lasting longer than 41 weeks." *The American Journal on Managed Care*, 2: 814-818, **1996**.
  18. Mercer BM, Goldenberg RL, Das A, Moawad AH, Iams JD, Meis PJ, Copper RL, Johnson F, Thom E, McNellis D, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, and Roberts J, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "The preterm prediction study: A clinical risk assessment system." *American Journal of Obstetrics and Gynecology*, 174:1885-1895, **1996**.
  17. Goldenberg RL, Thom E, Moawad AH, Johnson F, Roberts J, and Caritis SN for the NICHD MFMU Network. "The preterm prediction study: Fetal fibronectin, Bacterial Vaginosis, and Peripartum Infection." *Obstetrics and Gynecology*, 87.5:1-5, **1996**.
  16. Meis PJ, Das A, Thom E, McNellis D, and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Reply to: Questions for the study of infections and preterm labor." *American Journal of Obstetrics and Gynecology*, 175:754-755, **1996**.
  15. Meis PJ, Das A, Thom E, McNellis D and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. "Reply to: Preterm delivery and bacterial vaginosis – Logistic regression analysis." *American Journal of Obstetrics and Gynecology*, 175:754, **1996**.
  14. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, Thom E, McNellis D, Copper RL, Johnson F, Roberts JM, and the National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. "The length of the cervix and the risk of

- spontaneous premature delivery.” *The New England Journal of Medicine*, 334.9: 567-572, **1996**.
13. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, and McNellis D, for the NICHD Maternal-Fetal Medicine Units Network. “The preterm prediction study: Fetal fibronectin testing and spontaneous preterm birth.” *Obstetrics and Gynecology*, 87:643-648, **1996**.
  12. Meis PJ, Goldenberg RL, Mercer B, Moawad A, Das A, McNellis D, Johnson F, Iams JD, Thom E, Andrews WW and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. “The preterm prediction study: Significance of vaginal infections.” *American Journal of Obstetrics and Gynecology*, 173:1231-1235, **1995**.
  11. Guinn D, Goldenberg R, Hauth J, Andrews WW, Thom E, and Romero R. “Risk factors for the development of preterm premature rupture of the membranes after arrest of preterm labor.” *American Journal of Obstetrics and Gynecology*, 173:1310-1315, **1995**.
  10. Sibai BM, Caritis SN, Thom E, Shaw K, McNellis D, and the National Institute of Child Health and Human Development Maternal-Fetal Medicine Network. “Low-dose aspirin in nulliparous women: Safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications.” *American Journal of Obstetrics and Gynecology*, 172:1553-1557, **1995**.
  9. Sibai BM, Gordon T, Thom E, Caritis SN, Klebanoff M, McNellis D, and Paul RH. “Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter study.” *American Journal of Obstetrics and Gynecology*, 172: 642-648, **1995**.
  8. Landon M, McNellis D, Harger J, Mercer B, and Thom E. Reply to: Prevention of neonatal group B streptococcal infection. *Obstetrics and Gynecology*, 85:160-161, **1995**.
  7. McNellis D and Caritis S. Reply to: On Prolonged Pregnancy. *American Journal of Obstetrics and Gynecology*, 172:1321-1322, **1995**.
  6. Caritis SN, Thom E and McNellis D. Reply to: Comment on the effectiveness of induction of labor for postterm pregnancy. *American Journal of Obstetrics and Gynecology*, 172:241, **1995**.
  5. Landon MB, Harger J, McNellis D, Mercer B and Thom EA, for the MFMU Network of the NICHD. “Prevention of neonatal group B streptococcal infection.” *Obstetrics and Gynecology*, 84: 460-462, **1994**.
  4. Romero R and Thom E. “Reply to: Randomized controlled trials of antibiotics in preterm labor.” *American Journal of Obstetrics and Gynecology*, 171: 865-866, **1994**.

3. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "A clinical trial of induction of labor versus expectant management in postterm pregnancy." *American Journal of Obstetrics and Gynecology*, 170:716-723, **1994**.
2. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, Paul RH, Romero R, Witter F, Rosen M, Depp R, and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. "Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women." *The New England Journal of Medicine*, 329:1213-12180, **1993**.
1. Romero R, Sibai B, Caritis S, Paul R, Depp R, Rosen M, Klebanoff M, Sabo V, Evans J, Thom E, Cefalo R and McNellis D. "Antibiotic treatment of preterm labor with intact membranes: A multicenter, randomized, double-blinded, placebo-controlled trial." *American Journal of Obstetrics and Gynecology*, 169:764-774, **1993**.

## **MEDICAL INFORMATION MANAGEMENT SYSTEMS (MIMS)**

1. Gordon, T. Factors associated with serum alkaline phosphatase level. *Archives of Pathology and Laboratory Medicine*, 117:187-190, **1993**.

## **MEDICAL THERAPY OF PROSTATIC SYMPTOMS (MTOPS)**

5. Johnson II T, Burrows P, Kusek J, Nyberg L, Tenover JL, Lepor H, Roehrborn C. "The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men with Benign Prostatic Hyperplasia." *The Journal of Urology*, 178: 2045-2051, **2007**.
4. McConnell JD, Claus RG, Bautista OM, Andriole Jr. GL, Dixon CM, Kusek JW, Lepor H, McVary K, Nyberg Jr. LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM and Smith JA for the MTOPS Research Group. "The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia." *The New England Journal of Medicine*, 349.25:2387-98, **2003**.

3. Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H, for the MTOPS Research Group. "Study Design of the Medical Therapy of Prostatic Symptoms (MTOPS) Trial." *Controlled Clinical Trials*, 24.2:224-243, **2003**.
2. Kusek JW, Ahrens A, Burrows PK, Clarke HS, Foster HE, Hanson K, Jacobs SC, Kirkemo A, O'Berry K, and Pavlik VN. Recruitment for a Clinical Trial of Drug Treatment for Benign Prostatic Hyperplasia. *Urology*, 59: 63-67, **2002**.
1. Medical Therapy of Prostatic Symptoms Biostatistical Coordinating Center. "Group Sequential Procedure for the Interim Analysis of the Primary Outcome." *Presented to the External Advisory Board*, September **1996**.

## **MYOCARDIAL INFARCTION AND THE ROLE OF ORAL CONTRACEPTIVES**

2. Krueger DE, Ellenberg SS, Bloom S., et al. Risk factors for fatal heart attack in young women. *American Journal of Epidemiology*, 113:357-370, **1981**.
1. Krueger DE, Ellenberg SS, Bloom S, et al. Fatal myocardial infarction and the role of oral contraceptives. *American Journal of Epidemiology*, 111:655-674, **1980**.

## **NATIONAL COOPERATIVE GALLSTONE STUDY**

20. Fisher RL, Hofmann AF, Converse JL, Rossi SS and Lan SP. The lack of relationship between hepatotoxicity and lithocholic acid sulfation in biliary bile acids during chenodiol therapy in the National Cooperative Gallstone Study. *Hepatology*, 14:454-463, **1991**.
19. Canner PL, Gatewood LC, White C, Lachin JM and Schoenfield LJ. External monitoring of a data coordinating center: Experience of the National Cooperative Gallstone Study. *Controlled Clinical Trials*, 8:1-11, **1987**.

18. Stellard F, Klein PD, Hofmann AF and Lachin JM. Mass spectrometry identification of biliary bile acids in bile from patients with gallstones before and during treatment with chenodeoxycholic acid. *Journal of Laboratory and Clinical Medicine*, 105:504-513, **1985**.
17. Thistle JL, Cleary PA, Lachin JM, Tyor MP, Hersh T, The Steering Committee, and The National Cooperative Gallstone Study Group. The natural history of cholelithiasis: The National Cooperative Gallstone Study. *Annals of Internal Medicine*, 101:171-175, **1984**.
16. Marks JW, Lan SP, The Steering Committee, and The National Cooperative Gallstone Study Group. Low dose chenodiol to prevent gallstone recurrence after dissolution therapy. *Annals of Internal Medicine*, 100:376-381, **1984**.
15. Marks JW, Croke G, Gochman N, Hofmann AF, Lachin JM, Schoenfield LJ, Tyor MP, the Steering Committee and the National Cooperative Gallstone Study Group. Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS). *Controlled Clinical Trials*, 5:1-12, **1984**.
14. Grundy SM, Lan S, Lachin J, the Steering Committee and the National Cooperative Gallstone Study Group. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). *The Journal of Clinical Investigation*, 73:1156-1166, **1984**.
13. Hofmann AF and Lachin JM. Biliary bile acid composition and cholesterol saturation. *Gastroenterology*, 84:1075-1077, **1983**.
12. Schoenfield LJ, Grundy SM, Hofmann AF, Lachin J, Thistle JL and Tyor MP, for the National Cooperative Gallstone Study Group. The National Cooperative Gallstone Study viewed by its investigators. *Gastroenterology*, 84:644-655, **1983**.
11. Habig RL, Thomas P, Lippel K, Anderson D and Lachin JM. Central laboratory quality control in the National Cooperative Gallstone Study. *Controlled Clinical Trials*, 4:101-123, **1983**.
10. Lachin JM, Schoenfield LJ, and the National Cooperative Gallstone Study Group. Effects of dose relative to body weight in the National Cooperative Gallstone Study: A fixed-dose trial. *Controlled Clinical Trials*, 4:125-131, **1983**.
9. Phillips MJ, Fisher RL, Anderson DW, Lan S, Lachin JM, Boyer JL, and the Steering Committee for the National Cooperative Gallstone Study Group. Ultrastructural evidence of intrahepatic cholestasis before and after chenodeoxycholic acid therapy in patients with cholelithiasis: The National Cooperative Gallstone Study. *Hepatology*, 3:209-220, **1983**.
8. Hofmann AF, Grundy SM, Lachin JM, Lan SP, et al. Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the

- National Cooperative Gallstone Study. *Gastroenterology*, 83:738-752, **1982**.
7. Fisher RL, Anderson DW, Boyer JL, Ishak K, Klatskin G, Lachin JM, Phillips MJ, and The Steering Committee for the National Cooperative Gallstone Study Group. A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: The National Cooperative Gallstone Study. *Hepatology*, 2:187-201, **1982**.
  6. Albers JJ, Grundy SM, Cleary PA, Small DM, Lachin JM, Schoenfield LJ, and the National Cooperative Gallstone Study Group. National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. *Gastroenterology*, 82:638-646, **1982**.
  5. Schoenfield LJ, Lachin JM, The Steering Committee and The National Cooperative Gallstone Study Group. Chenodial (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. *Annals of Internal Medicine*, 95:257-282, **1981**.
  4. Lasser EC, Amberg JR, Baily NA, Varady P, Lachin J, Okun R and Schoenfield L. Validation of a computer-assisted method for estimating the number and volume of gallstones visualized by cholecystography. *Investigative Radiology*, 16:342-347, **1981**.
  3. Marks JW, Sue SO, Pearlman BJ, Bonorris GG, Varady P, Lachin JM and Schoenfield LJ. Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones. *Journal of Clinical Investigation*, 68:1190-1196, **1981**.
  2. Lachin JM, Marks JW, Schoenfield LJ, the NCGS Protocol Committee and the National Cooperative Gallstone Study Group. Design and methodological considerations in the National Cooperative Gallstone Study: A multi-center clinical trial. *Controlled Clinical Trials*, 2:177-229, **1981**.
  1. Marks JW, Bonorris GG, Chung A, Coyne MJ, Okun R, Lachin JM and Schoenfield LJ. Feasibility of low-dose and intermittent chenodeoxycholic acid therapy of gallstones. *The American Journal of Digestive Diseases*, 22:856-860, **1977**.

## NATIONAL EXERCISE AND HEART DISEASE PROJECT

8. Naughton J, Dorn J, Oberman A, Gorman P and Cleary P. Maximal exercise systolic pressure, exercise training, and mortality in myocardial infarction patients. *The American Journal of Cardiology*, 85:416-420, **2000**.
7. LaRosa JC, Cleary P, Muesing RA, Gorman P, Hellerstein HK and Naughton J. Effect of long-term moderate physical exercise on plasma lipoproteins. *Archives of Internal Medicine*, 142:2269-2274, **1982**.
6. Oberman A, Cleary P, LaRosa JC, Hellerstein HK and Naughton J. Changes in risk factors among participants in a long-term exercise rehabilitation program. *Advances in Cardiology*, 31:168-175, **1982**.
5. Stern MJ and Cleary P. The National Exercise and Heart Disease Project. Long-term psychosocial outcome. *Archives of Internal Medicine*, 142:1093-1097, **1982**.
4. Shaw LW for The National Exercise and Heart Disease Project. Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after a myocardial infarction. *American Journal of Cardiology*, 48:39-46, **1981**.
3. Stern MJ and Cleary P. The National Exercise and Heart Disease Project. Psychosocial changes observed during a low-level exercise program. *Archives of Internal Medicine*, 141:1463-1467, **1981**.
2. Naughton J et al. In Wenger, N, editor, "The National Exercise and Heart Disease Project: Development, Recruitment and Implementation." Philadelphia, FA Davis: 205-221, **1978**.
1. Naughton J et al. The National Exercise and Heart Disease Project. The pre-randomization exercise program report. *Cardiology*, 63:352-367, **1978**.

## NEONATAL INTENSIVE CARE UNITS NETWORK (NICU)

29. Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, Smeriglio VL, Finnegan LP, Maza PL, and Verter J. "Acute Neonatal Effects of Cocaine Exposure During Pregnancy." *Archives of Pediatrics & Adolescent Medicine*, 159:824-834, **2005**.

28. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S, Donovan EF, Close NC, and Das A for the National Institute of Child Health and Human Development Neonatal Research Network. Effects of Early Erythropoietin Therapy on the Transfusion Requirements of Preterm Infants Below 1250 Grams Birth Weight: A Multicenter, Randomized, *Controlled Trial*. *Pediatrics*, 108: 934-942, **2001**.
27. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, Simon NP, Wilson DC, Broyles S, Bauer CR, Delaney-Black V, Yolton KA, Fleisher BE, Papile L, and Kaplan MD. Neurodevelopmental and Functional Outcomes of Extremely Low Birth Weight Infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. *Pediatrics*, 105: 1216-1226, **2000**.
26. Donovan EF, Ehrenkranz RA, Shankaran S, Stevenson DK, Wright LL, Younes N, Fanaroff AA, Korones SB, Stoll BJ, Tyson JE, Bauer CR, Lemons JA, Oh W, and Papile L, for the National Institute of Child Health and Human Development Neonatal Research Network. Outcomes of very- low- birth-weight twins cared for in the NICHD Neonatal Research Networks neonatal intensive care units. *American Journal of Obstetrics and Gynecology*, 179:742-749, **1998**.
25. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, Tyson JE, Philips JB III, Edwards W, Lucey JF, Catz CS, Shankaran S, Oh W, and Verter J for the National Institute of Child Health and Human Development Neonatal Research Network. The incidence, presenting features, risk factors, and significance of septicemia in low birthweight infants. *Pediatric Infectious Disease Journal*, 17:593-598, **1998**.
24. Bada HS, Bauer CR, Shankaran S, Lester BM, Wright LL, Verter J, Smeriglio VL, Finnegan L, and Maza PL. Central and autonomic nervous systems' signs associated with in utero exposure to cocaine/opiates. *Annals of the New York Academy of Sciences*, 846:431-434, **1998**.
23. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB, Lemons JA, Fanaroff AA, and Stevenson DK. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. *The New England Journal of Medicine*, 338:1112-1118, **1998**.
22. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA and Oh W. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. *The New England Journal of Medicine*, 337:466-471, **1997**.

21. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. *Pediatrics*, 99:838-845, **1997**.
20. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *The New England Journal of Medicine*, 336:597-604, **1997**.
19. Kennedy KA, Stoll BJ, Ehrenkranz RA, Oh W, Wright LL, Stevenson DK, Lemons JA, Sowell A, Mele L, Tyson JE and Verter J, for the NICHD Neonatal Research Network. Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low? *Early Human Development*, 49:19-31, **1997**.
18. Vreman HJ, Verter J, Oh W, Fanaroff AA, Wright LL, Lemons JA, Shankaran S, Tyson JE, Korones SB, Bauer CR, Stoll BJ, Papile LA, Donovan EF, Ehrenkranz RA and Stevenson DK. Interlaboratory variability of bilirubin measurements. *Clinical Chemistry*, 42:869-873, **1996**.
17. Tyson JE, Younes N, Verter J and Wright LL. Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight. *Journal of the American Medical Association*, 276:1645-1651, **1996**.
16. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, Fanaroff AA, Lemons JA, Donovan EF, Oh W, Stevenson DK, Ehrenkranz RA, Papile LA, Verter J and Wright LL. Early-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*, 129:72-80, **1996**.
15. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, Fanaroff AA, Lemons JA, Donovan EF, Oh W, Stevenson DK, Ehrenkranz RA, Papile LA, Verter J and Wright LL. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*, 129:63-71, **1996**.
14. Shankaran S, Bauer CR, Bain R, Wright LL and Zachary J, for the National Institute of Child Health and Human Development Neonatal Research Network. Prenatal and perinatal risk and protective factors for neonatal intracranial hemorrhage. *Archives of Pediatrics and Adolescent Medicine*, 150:491-497, **1996**.
13. Fanaroff AA, Wright LL, Stevenson DK, Shankaran S, Donovan EF, Ehrenkranz RA, Younes N, Korones SB, Stoll BJ, Tyson JE, Bauer CR, Oh W, Lemons JA, Papile LA and Verter J. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. *American Journal of Obstetrics and Gynecology*, 173:1423-1431, **1995**.

12. Wright LL and McNellis D. "National Institute of Child Health and Human Development (NICHD)-Sponsored Perinatal Research Networks." *Seminars in Perinatology*, 19:112-123, **1995**.
11. Wright LL, Horbar JD, Gunkel H, Verter J, Younes N, Andrews EB and Long W. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birth weight infants. *American Journal of Obstetrics and Gynecology*, 173:263-269, **1995**.
10. Hack M, Wright LL, Shankaran S, Tyson JE, Horbar JD, and Bauer CR and Younes N. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network, November 1989 to October 1990. *American Journal of Obstetrics and Gynecology*, 172:457-464, **1995**.
9. Shankaran S, Bauer CR, Bain R, Wright LL and Zachary J, for the NICHD Neonatal Research Network. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. *American Journal of Obstetrics and Gynecology*, 173:305-311, **1995**.
8. Wright LL, Verter J, Younes N, Stevenson D, Fanaroff AA, Shankaran S, Ehrenkranz RA and Donovan EF for the NICHD Neonatal Research Network. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: The NICHD Neonatal Research Network. *American Journal of Obstetrics and Gynecology*, 173:269-274, **1995**.
7. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, Philips JB, Edwards W, Lucey JF, Catz CS, Shankaran S and Oh W for the National Institute of Child Health and Human Development Neonatal Research Network. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. *The New England Journal of Medicine*, 330:1107-1113, **1994**.
6. Stevenson DK, Vreman HJ, Oh W, Fanaroff AA, Wright LL, Lemons JA, Verter J, Shankaran S, Tyson JE, Korones SB, Bauer CR, Stoll BJ, Papile LU, Okah F and Ehrenkranz RA. Bilirubin production in healthy term infants as measured by carbon monoxide in breath. *Clinical Chemistry*, 40: 1934-1939, **1994**.
5. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, Shankaran S, Oh W, Fletcher BD, Bauer CR, Tyson JE, Lemons JA, Donovan EF, Stoll BJ, Stevenson DD, Papile LA, and Philips J, for the National Institute of Child Health and Human Development Neonatal Research Network. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. *The Journal of Pediatrics*, 123:757-766, **1993**.

4. Horbar JD, Wright EC, Onstad L and the Members of the National Institute of Child Health and Human Development Neonatal Research Network. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth. *Pediatrics*, 92:191-196, **1993**.
3. Horbar JD, Onstad L, Wright E; the National Institute of Child Health and Human Development Neonatal Research Network. Predicting mortality risk for infants weighing 501 to 1500 grams at birth: A National Institutes of Health Neonatal Research Network report. *Critical Care Medicine*, 21:12-18, **1993**.
2. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E and Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. *Pediatrics*, 87:587-597, **1991**.
1. Malloy MH, Onstad L, Wright E, and the National Institute of Child Health and Human Development Neonatal Research Network. The effect of cesarean delivery on birth outcome in very low birth weight infants. *Obstetrics and Gynecology*, 77:498-503, **1991**.

## **OPTIC NEURITIS TREATMENT TRIAL**

27. Cole SR, Beck RW, Moke PS, Gal RL, Long DT and the Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: Experience of the ONTT. *Investigative Ophthalmology and Visual Science*, 41:1017-1021, **2000**.
26. Hausser SL, Oksenburg JR, Lincoln R, Garovoy J, Beck RW, Cole SR, Moke PS, Kip KE, Gal RL, Long DT and the Optic Neuritis Study Group. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. *Neurology*, 54:1859-1861, **2000**.
25. Cole SR, Beck RW, Moke PS, Kaufman DI and Tourtellotte WW for the Optic Neuritis Study Group. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. *Neurology*, 51:885-887, **1998**.
24. Cleary PA, Beck RW, Bourque LB, Backlund JC and Miskala PH for the Optic Neuritis Study Group. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. *Journal of Neuro-Ophthalmology*, 17:18-28, **1997**.
23. Trobe JD, Beck RW, Moke PS and Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. *American Journal of Ophthalmology*, 121:547-553, **1996**.
22. Rolak LA, Beck RW, Paty DW, Touretellotte WW, Whitaker JN and Rudick RA for the Optic Neuritis Study Group. Cerebrospinal fluid in

- acute optic neuritis: experience of the Optic Neuritis Treatment Trial. *Neurology*, 46:368-372, **1996**.
21. Anderson MM, Boly LD and Beck RW for the Optic Neuritis Study Group. Remote Clinic/Patient Monitoring for multicenter trials. *Controlled Clinical Trials*, 17:407-414, **1996**.
  20. Beck RW and Trobe JD for the Optic Neuritis Study Group. What we have learned from the Optic Neuritis Treatment Trial. *Ophthalmology*, 102:1504-1508, **1995**.
  19. Beck RW and Trobe JD for the Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: Putting the results in perspective. *Journal of Neuro-Ophthalmology*, 15:131-135, **1995**.
  18. Beck RW for the Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: Three year follow-up results. *Archives of Ophthalmology*, 113:136-137, **1995**.
  17. Keltner JL, Johnson CA, Spurr JO and Beck RW for the Optic Neuritis study Group. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. *Archives of Ophthalmology*, 112:946-953, **1994**.
  16. Beck RW, Cleary PA, Backlund J, The Optic Neuritis Study Group. The course of visual recovery after optic neuritis: Experience of the Optic Neuritis Treatment Trial. *Ophthalmology*, 101:1771-1778, **1994**.
  15. Beck RW, Cleary PA and the Optic Neuritis Study Group. Recovery from severe visual loss in optic neuritis. *Archives of Ophthalmology*, 111:300, **1993**.
  14. Keltner JL, Johnson CA, Spurr JO and Beck RW and the Optic Neuritis Study Group. Baseline visual field profile of optic neuritis: The experience of the Optic Neuritis Treatment Trial. *Archives of Ophthalmology*, 111:231-234, **1993**.
  13. Beck RW, Kupersmith MJ, Cleary PA, Katz B, and The Optic Neuritis Study Group. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the Optic Neuritis Treatment Trial. *Ophthalmology*, 100:691-698, **1993**.
  12. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH and the Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. *The New England Journal of Medicine*, 329:1764-1769, **1993**.
  11. Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO and the Optic Neuritis Study Group. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). *Controlled Clinical Trials*, 14:143-159, **1993**.

10. Beck RW, Diehl L, Cleary PA and the Optic Neuritis Study Group. Technical Note. The Pelli-Robson letter chart: Normative data for young adults. *Clinical Vision Science*, 8:207-210, **1993**.
9. Chrousos GA, Kattah JC, Beck RW, Cleary PA and the Optic Neuritis Study Group. Side effects of glucocorticoid treatment: Experience of the Optic Neuritis Treatment Trial. *Journal of the American Medical Association*, 269:2110-2112, **1993**.
8. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI and the Optic Neuritis Study Group. Brain magnetic resonance imaging in acute optic neuritis: Experience of the Optic Neuritis Study Group. *Archives of Neurology*, 50:841-846, **1993**.
7. Beck RW, Cleary PA and the Optic Neuritis Study Group. Optic Neuritis Treatment Trial. One-year follow-up results. *Archives of Ophthalmology*, 111:773-775, **1993**.
6. Cleary PA, Beck RW, Anderson MM, Kenny DJ, Backlund JY, Gilbert PR and the Optic Neuritis Study Group. Design, methods, and conduct of the Optic Neuritis Treatment Trial. *Controlled Clinical Trials*, 14:123-142, **1993**.
5. Beck RW and the Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis: A need to change treatment practices. *Neurology*, 42:1133-1135, **1992**.
4. Beck RW and the Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: Implications for clinical practice. *Archives of Ophthalmology*, 110:331-332, **1992**.
3. Beck RW, Cleary PA et al. and the Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. *The New England Journal of Medicine*, 326:581-588, **1992**.
2. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. *Archives of Ophthalmology*, 109:1673-1678, **1991**.
1. Beck RW. The Optic Neuritis Treatment Trial. *Archives of Ophthalmology*, 106:1051-1053, **1988**.

## PEPTIDE T

1. Heseltine PNR, Goodkin K, Atkinson H, Vitiello B, Rochon J et al. Randomized double-blind placebo-controlled trial of Peptide T for HIV associated cognitive impairment. *Archives of Neurology*, 55:41-51, **1998**.

## PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITION (PEACE)

11. Hsia J, Jablonski K, Murguia Rice M, Sabatine M, Zabalgoitia M, Maggioni A, Cuddy T, Domanski M, Geller N, Flaker G, Solomon S, Omland T, Rouleau J. "Sudden Cardiac Death in Patients with Stable Coronary Artery Disease and Preserved Left Ventricular Systolic Function." *American Journal of Cardiology*, 101:457-461, **2008**.
10. Solomon S, Lin J, Solomon C, Jablonski K, Murguia Rice M, Steffes M, Domanski M, Hsia J, Gersh B, Arnold JM, Rouleau J, Braunwald E, Pfeffer M. "Influence of Albuminuria on Cardiovascular Risk in Patients with Stable Coronary Artery Disease." *Circulation*, 116, **2007**.
9. Sabatine M, Morrow D, O'Donoghue M, Jablonski K, Murguia Rice M, Solomon S, Rosenberg Y, Domanski M, Hsia J. "Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients with Stable Coronary Artery Disease." *Arterioscler Thromb Vasc Biol*. 27:2463-2469, **2007**.
8. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, for the PEACE Investigators. "Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease: The PEACE Trial." *Journal of the American College of Cardiology*, 50.3: 205-214, **2007**.
7. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JMO, Tardif J-C, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA, for the PEACE Investigators. "Long-Term Trandolapril Treatment Is Associated with Reduced Aortic Stiffness: The Prevention of Events with Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy." *Hypertension*, 49(6): 1271-7, **2007**.
6. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E, for the PEACE Investigators. "Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients with Stable Coronary Artery Disease." *Circulation*, 115.12: 1528-36, **2007**.
5. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E, for the Prevention of Events with ACE Inhibition (PEACE) Investigators. "Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in

- patients with chronic stable coronary disease in the Prevention of Events with ACE Inhibition (PEACE) trial.” *Circulation*, 114(1):26-31, **2006**.
4. Domanski MJ, Jablonski KA, Rice MM, Fowler, SE, Braunwald E, for the PEACE Investigators. “Obesity and cardiovascular events in patients with established coronary disease.” *European Heart Journal*, 27(12):1416-22, **2006**.
  3. The PEACE Trial Investigators. “Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease.” *The New England Journal of Medicine*, 351:2058-2068, **2004**.
  2. Pfeffer MA, Domanski M, Verter J, Dunlap M, Flaker GC, Gersh B, Hsia J, Goldberg AD, Limacher MC, Maggioni AP, Rosenberg Y, Rouleau J, Warnica JW, Wasserman AG, and Braunwald E. “The Continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.” *American Heart Journal*, 142:375-377, **2001**.
  1. Pfeffer MA, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J and Braunwald E. “Prevention of events with angiotensin-converting enzyme inhibition (The PEACE Study Design).” *The American Journal of Cardiology*, 82:25H-30H, **1998**.

## **PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DIAGNOSIS (PIOPED II)**

3. Stein PD, Woodard PK, Weg JG, Wakefield TW, Tapson VF, Sostman HD, Sos TA, Quinn DA, Leeper KV, Hull RD, Hales CA, Gottschalk A, Goodman LR, Fowler SE, Buckley JD. “Diagnostic Pathways in Acute Pulmonary Embolism: Recommendations of the PIOPED II Investigators.” *Radiology*, 242: 15-21, **2007**.
2. Stein PD, Fowler SE, et al. for the PIOPED II Investigators. “Multidetector Computed Tomography for Acute Pulmonary Embolism.” *NEJM* 354.22: 2317-2327, **2006**.
1. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Leeper KV, Popovich J, Quinn DA, Sos TA, Sostman HD, Tapson VF, Wakefield TW, Weg JG, Woodard PK for the PIOPED II Investigators. “Multidetector Spiral CT For Acute Pulmonary Embolism: Results of The PIOPED II Trial.” *New England Journal of Medicine*, 354:2317-27, **2006**.

## **ROUTINE ANTENATAL DIAGNOSTIC IMAGING WITH ULTRASOUND (RADIUS)**

6. Harlow BL, Frigoletto FD, Cramer DW, Evans JK, Bain RP, Ewigman B, McNellis D and the RADIUS Study Group. Epidemiologic predictors of cesarean section in nulliparous patients at low risk. *American Journal of Obstetrics and Gynecology*, 172:156-162, **1995**.
5. Crane JP, LeFevre ML, Winborn RC, Evans JK, Ewigman BG, Bain RP, Frigoletto FD, McNellis D and the RADIUS Study Group. A randomized trial of prenatal ultrasonographic screening: Impact on the detection, management, and outcome of anomalous fetuses. *General Obstetrics and Gynecology*, 171:392-399, **1994**.
4. Bromley B, Frigoletto FD, Harlow BL, Evans JK and Benacerraf BR. Biometric measurements in fetuses of different race and gender. *Ultrasound in Obstetrics and Gynecology*, 3:395-402, **1993**.
3. LeFevre ML, Bain RP, Ewigman BG, Frigoletto FD, Crane JP, McNellis D and the RADIUS Study Group. A randomized trial of prenatal ultrasonographic screening: Impact on maternal management and outcome. *American Journal of Obstetrics and Gynecology*, 169:483-489, **1993**.
2. Ewigman BG, Crane JP, Frigoletto FD, LeFevre ML, Bain RP, McNellis D and the RADIUS Study Group. Effect of prenatal ultrasound screening on perinatal outcome. *The New England Journal of Medicine*, 329:821-827, **1993**.
1. Ewigman B, Bain RP, Crane JP and McNellis D. Letter to the editors. Ethics and routine ultrasonography in pregnancy. *American Journal of Obstetrics and Gynecology*, 163:256-257, **1990**.

## **SARCOIDOSIS GENETIC ANALYSIS (SAGA)**

2. Judson MA, Hirst K, Iyengar SK, Rybicki BA, El ghormli L, Baughman RP, Donohue JF, Elston RC, Kavuru MS, Maliarik M, Moller DR, Newman LS, Rabin DL, Rossman MD, Teirstein AS, Iannuzzi MC for the SAGA Study Consortium. "Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings." *Chest*, 130:855-862, **2006**.
1. Gray-McGuire C, Sinha R, Iyengar S, Millard C, Rybicki BA, Elston RC, Iannuzzi MC for the SAGA Study Consortium. "Genetic Characterization and Fine Mapping of Susceptibility Loci for Sarcoidosis in African Americans on Chromosome 5." *Human Genetics*, 120(3):420-430, **2006**.

## STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): (TODAY AND HEALTHY)

2. STOPP-T2D/TODAY Study Group. "Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY): A Study of the Comparative Efficacy of Metformin Alone or in Combination with Rosiglitazone or Lifestyle Intervention in Adolescents with Type 2 Diabetes." *Pediatric Diabetes*, 8.2: 74-87, **2007**.
1. STOPP-T2D Prevention Study Group. "Presence of Diabetes Risk Factors in a Large U.S. Eighth-Grade Cohort." *Diabetes Care*, 29: 212-217, **2006**.

## TYPE 1 DIABETES TRIALNET (TRIALNET)

4. Chase P, Leschek E, Krause-Steinrauf H, Chritton S, Asare S, Adams S, Skyler S, Clare-Salzler M. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes. A Pilot Trial. *ICAN: Infant, Child, and Adolescent Nutrition* **2009**; 1; 09.
3. Greenbaum CJ, Mandrup-Poulsen T, Friedenber-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group. Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of  $\beta$ -Cell Function in Therapeutic Trials in Type 1 Diabetes. *Diabetes Care* **2008**; 31:1966-1971
2. Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatric Diabetes* 2008: [Epub ahead of print] doi: 10.1111/j.1399-5448.2008.00464
1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop. *Diabetes* **2004**; 53:250-264.

## VIETNAM HEAD INJURY STUDY

4. Grafman J, Salazar A, Weingartner H, Vance S and Amin D. The relationship of brain-tissue loss volume and lesion location to cognitive deficit. *The Journal of Neuroscience*, 6:301-307, **1986**.
3. Ludlow C, Rosenberg J, Fair C, Buck D, Schlesselman S and Salazar A. Brain lesions associated with nonfluent aphasia fifteen years following penetrating head injury. *Brain*, 109:55-80, **1986**.
2. Salazar AM, Grafman J, Schlesselman S, Vance SC, Mohr JP, Carpenter M, Pevsner P, Ludlow C and Weingartner H. Penetrating war injuries of the basal forebrain: Neurology and cognition. *Neurology*, 36:459-465, **1986**.
1. Salazar AM, Jabbari B, Vance SC, Grafman J, Amin D, and Dillon JD. Epilepsy after penetrating head injury. I: Clinical correlates: A report of the Vietnam Head Injury Study. *Neurology*, 35:1406-1414, **1985**.

## THE WOMEN'S HEALTH STUDY

7. Stadel BV and Schlesselman S. Extent of surgery for pelvic inflammatory disease in relation to duration of intrauterine device use. *Obstetrics and Gynecology*, 63:171-177, **1984**.
6. Heartwell SF and Schlesselman S. Risk of uterine perforation among users of intrauterine devices. *Obstetrics and Gynecology*, 61:31-36, **1983**.
5. Burkman R, Schlesselman S, McCaffrey L, Gupta PK and Spence M. The relationship of genital tract actinomycetes and the development of pelvic inflammatory disease. *American Journal of Obstetrics and Gynecology*, 143:585-589, **1982**.
4. Foreman H, Stadel BV and Schlesselman S. Intrauterine device usage and fetal loss. *Obstetrics and Gynecology*, 58:669-677, **1981**.
3. Burkman RT and the Women's Health Study. Association between intrauterine device and pelvic inflammatory disease. *Obstetrics and Gynecology*, 57:269-276, **1981**.
2. Ory HW and the Women's Health Study. Ectopic pregnancy and intrauterine contraceptive devices: New perspectives. *Obstetrics and Gynecology*, 57:137-144, **1981**.
1. Huggins GR and the Women's Health Study. IUD use and unexplained vaginal bleeding. *Obstetrics and Gynecology*, 58:409-416, **1981**.

## OTHER MEDICAL INVESTIGATIONS

51. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G for the ADOPT Study Group. "Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy." *The New England Journal of Medicine*, 355: 2427-43, [Correction (356: 1387-8, 2007)] **2006**.
50. Viberti G, Lachin JM, Holman RR, Zinman B, Haffner SM, Heise MA, Jones NP, Kravitz BG, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group. "A Diabetes Outcome Progression Trial (ADOPT): Baseline Characteristics of Type 2 Diabetic Patients in North America and Europe." *Diabetic Medicine*, 23.12: 1289-1294, **2006**.
49. Kahn SE, Zinman B, Haffner SM, O'Neill C, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC and the ADOPT Study Group. "Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes." *Diabetes*, 55: 2357-2364, **2006**.
48. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, and Freed MI. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. *Diabetes Care*, 25:1737-43, **2002**.
47. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, and Vinicor F. Implications of the United Kingdom Prospective Diabetes Study. *Diabetes Care*, 21: 2180-2184, **1998**.
46. Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, and Lachin JM. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: A meta-analysis of individual patient data. *Diabetes Care*, 19:1091-1096, **1996**.
45. Ron E, Preston DL, Mabuchi K, Thompson DE and Soda M. Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. *Radiation Research*, 137:S98-S112, **1994**.
44. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, Kamada N, Dohy H, Matsui T, Nonaka H, Thompson DE, Soda M and Mabuchi K. Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiation Research*, 137:S68-S97, **1994**.

43. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Izumi S, and Preston DL. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. *Radiation Research*, 137:S17-S67, **1994**.
42. Mabuchi K, Soda M, Ron E, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Preston DL and Thompson DE. Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies. *Radiation Research*, 137:S1-S16, **1994**.
41. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP and White BG for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. *The New England Journal of Medicine*, 329:149-155, **1993**.
40. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perillo RP, Stevens CE, Hollingsworth CG, and the National Heart, Lung, and Blood Institute Study Group. Long-term mortality after transfusion-associated non-A, non-B hepatitis. *The New England Journal of Medicine*, 327:1906-1911, **1992**.
39. Kimmel PL, Phillips TM, Phillips E and Bosch JP. Effect of renal replacement therapy on cellular cytokine production in patients with renal disease. *Kidney International*, 38:129-135, **1990**.
38. Lachin John et al. Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. *Diabetes*, 37:1000-1004, **1988**.  
Lachin, John et al. Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. *Diabetes Care*, 11:592-597, **1988**.
37. Gordon T and Doyle JT. Weight and mortality in men: The Albany Study. *International Journal of Epidemiology*, 17:77-81, **1988**.
36. Gordon T and Doyle JT. Drinking and mortality: The Albany Study: *American Journal of Epidemiology*, 125:263-270, **1987**.
35. Steinberg WM, and Schlesselman SE. Treatment of acute pancreatitis. Comparison of animal and human studies. *Gastroenterology*, 93:1420-1427, **1987**.
34. Lipson A, Stoy DB, LaRosa JC, Muesing RA, Cleary PA, Miller VT, Gilbert PR and Stadel B. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study. *Contraception*, 34:121-134, **1986**.
33. Schulof RS, Chorba TL, Cleary PA, Palaszynski SR, Alabaster O and Goldstein AL. T-Cell abnormalities after mediastinal irradiation for lung cancer. *Cancer*, 55:974-983, **1985**.

32. Gordon T and Doyle JT. Drinking and coronary heart disease. The Albany Study. *American Heart Journal*, 110:331-334, **1985**.
31. Fisher M and Gordon T. The relation of drinking and habits to diet: the Lipid Research Clinics Prevalence Study. *American Journal Clinical Nutrition*, 41:623-630, **1985**.
30. Schmidt SB, Wasserman AG, Muesing RA, Schlesselman SE, LaRosa JC, and Ross AM. Lipoprotein and apolipoprotein levels in angiographically defined coronary atherosclerosis. *American Journal of Cardiology*, 55:1459-1462, **1985**.
29. Gordon T and Kannel WB. Drinking and mortality: The Framingham Study. *American Journal of Epidemiology*, 120:97-107, **1984**.
28. Wasserman AG, Katz RJ, Varghese PJ, Leiboff RH, Bren GG, Schlesselman SE, Varma VM, Reba RC and Ross AM. Exercise radionuclide ventriculographic responses in hypertensive patients with chest pain. *The New England Journal of Medicine*, 311:1276-1280, **1984**.
27. Wasserman AG, Reiss L, Katz RJ, Leiboff R, Cleary P, Varma VM, Reba RC and Ross AM. Insensitivity of the cold pressor stimulation test for the diagnosis of coronary artery disease. *Circulation*, 67:1189-1193, **1983**.
26. Gordon T and Kannel WB. Drinking and its relation to smoking, BP, blood lipids and uric acid: The Framingham Study. *Archives of Internal Medicine*, 143:1366-1374, **1983**.
25. Kozarevic D, Vojvodic N, Gordon T, Kaelber CT, McGee D and Zukel WJ. Drinking habits and death: The Yugoslavia Cardiovascular Disease Study. *International Journal of Epidemiology*, 12.2:145-155, June **1983**.
24. Gordon T and Kannel WB. Drinking habits and cardiovascular disease: The Framingham Study. *American Heart Journal*, 105:667-673, **1983**.
23. Hiller R and Krueger DE. Validity of a survey question as a measure of visual acuity impairment. *American Journal of Public Health*, 73:93-96, **1983**.
22. Wasserman AG, Katz RJ, Cleary P, Varma VM, Reba RC and Ross AM. Noninvasive detection of multivessel disease after myocardial infarction by exercise radionuclide ventriculography. *The American Journal of Cardiology*, 50:1242-1247, **1982**.
21. Kozarevic D, Racic Z, Gordon T, Kaelber CT, McGee D and Zukel WJ. Drinking habits and other characteristics. The Yugoslavia Cardiovascular Disease Study. *American Journal of Epidemiology*, 116:287-301, **1982**.
20. Hiller R, Sperduto RD and Krueger DE. Pseudoexfoliation, intraocular pressure, and senile lens changes in a population-based survey. *Archives of Ophthalmology*, 100:1080-1082, **1982**.

19. Hiller R, Sperduto RD and Krueger DE. Race, iris pigmentation and intraocular pressure. *American Journal of Epidemiology*, 115:674-683, **1982**.
18. Mantel N. Letter to the Editor : Age of mothers with breast cancer and sex of their children. *British Medical Journal*, 282:1472-1473, **1981**.
17. The Coronary Drug Project Research Group. Implications of findings in the Coronary Drug Project for secondary prevention trials in coronary heart disease. *Circulation*, 63:1342-1350, **1981**.
16. Davis CE, Gordon D, LaRosa J, Wood P and Halperin M. Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. *Circulation*, 62:24-30, **1980**.
15. Leibowitz HM, Krueger DE, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Survey of Ophthalmology*, 24:335-610, **1980**.
14. Krueger DE and Feldman JJ. Cancer data systems in the U.S.—National Center for Health Statistics. In Levin, DL, editor, *Cancer Epidemiology in the U.S.A. and the U.S.S.R.* NIH Pub. #80-2044, **1980**.
13. Armaly MF, Krueger DE, Maunder LR, Becker B, Hetherington J, Kolker AE, Levene RZ, Maumenee AE, Pollack IP, and Shaffer RN. Biostatistical Analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. *Archives of Ophthalmology*, 98:2163-2171, **1980**. **Abstract Only Available**
12. Krueger DE, Milton RC, and Maunder LR. The Framingham Eye Study: Introduction to the monograph. *Survey of Ophthalmology*, 24:614-620, **1980**.
11. Krueger DE. "Degenerative retinal diseases and exposure to light: Methods of epidemiological study." *Vision Research*, 20:1191-1194, **1980**.
10. Mantel N. Guar crispbread in the diabetic diet. *British Medical Journal*, 2:1589, **1979**.
9. Mantel N. Perinatal mortality by birth order. *British Medical Journal*, 2:1147, **1979**.
8. Cornfield J and Detre K. Selection on atherosclerosis as an explanation of the attenuated cholesterol-mortality relation in coronary heart disease populations. *American Journal of Epidemiology*, 110:716-723, **1979**.
7. Gordon T, Kannel WB and Halperin M. Predictability of coronary heart disease. *Journal of Chronic Diseases*, 32:427-440, **1979**.

6. Armaly MF, Krueger DE and Maunder L. Summary report of "Biostatistical Analysis of the Collaborative Glaucoma Study." In Krieglstein GK and Leydhecker W, editors, *Glaucoma Update: International Glaucoma Symposium, Nara, Japan, May 7-11, 1978*, Berlin: Springer-Verlag: 131-134, **1979**.
5. Wagner S and Mantel N. Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. *Cancer Research*, 38:2703-2708, **1978**.
4. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PJ, Neviasser RJ, Rubin BE and Varma VM. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. *Journal of Bone and Joint Surgery*, 60A, **1978**.
3. Wessler S, Kleiger R, Cornfield J and Teitelbaum SL. Coumarin therapy in acute myocardial infarction. A Hobson's choice. *Archives of Internal Medicine*, 134:774-779, **1974**.
2. Halperin M, Cornfield J and Mitchell SC. Letter to the editor. Effect of diet on coronary-heart-disease mortality. *The Lancet*, 2:438-439, **1973**.
1. Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. *Journal of the American Medical Association*, 217:1676-1687, **1971**.